

**PHARMACEUTICAL LAW & INDUSTRY
REPORT® INDEX-SUMMARY**

— Vol. 7, Nos. 1-43 pp. 1-1268
— Jan. 2-Oct. 30, 2009

A

**ABBREVIATED NEW DRUG APPLICATIONS
(ANDAs)**

Bioequivalence

—Data submission, FDA issues draft guidance, 471
—Product specific studies, FDA issues final recommendations, 685
—Studies, FDA issues rule, 98
Clobel patent infringement alleged (N.D. Tex.), 63
Generic drugs
—Allegra-D maker tries to block generic (D.N.J.), 119
—Avinza, infringement alleged over generic ANDA (D.N.J.), 1071
—Backlog addressed by FDA, 1257
—Blood pressure drugs, ANDAs infringe patent (D.N.J.), 938; appeal filed, 991
—Cardene, generic ANDA challenged (D.N.J.), 401
—Doryx generic ANDAs challenged as infringement, 14
—Fortamet, generic ANDA challenged (D. Del.), 97
—Truvada V drug ANDA infringes patent (S.D.N.Y.), 10
Lotrel low-dose ANDA challenged as infringement (D.N.J.), 13; dismissed, 201
Pataday. *See* PATADAY
Withdrawals not due to safety or effectiveness, FDA says, 19; 19 drugs withdrawn, 715

ACCREDITATION AND CERTIFICATION

Pfizer study subject protection program accredited, 417

ACCUTANE

Acne drug blamed for inflammatory bowel disease, new trial ordered (N.J. Super. Ct.), 313
Discontinued due to generic competition, 780
Expert witness excluded (M.D. Fla.), 1039
Failure-to-warn of suicide risk, maker wins summary judgment (11th Cir.), 705
Inflammatory bowel disease blamed on drug, jury verdict for plaintiff thrown out (Fla. Dist. Ct. App.), 1252

ACETAMINOPHEN

Prescription drugs, FDA panel urges ban, 802

ACTIMMUNE

Class action over off-label use marketing dismissed (N.D. Cal.), 583
Indictment of CEO over off-label use promotion upheld (N.D. Cal.), 675

ACTONEL

Bone-blocking drug, generic version challenged (D. Del.), 150
Osteoporosis drug patent upheld against generic maker (Fed. Cir.), 581

ACTOS

Diabetes drug patent dispute, attorneys' fees upheld (U.S., rev den), 1166

ACULAR

Eye inflammation treatment patent upheld (U.S., rev den), 117

ACZONE

Acne drug ad overstates efficacy, FDA says, 1001

ADDERAL XR

Amphetamine capsules, generic maker to get license (D. Colo.), 1195

ADVERSE EFFECTS *See also* SAFETY

Mixing prescription and OTC drugs, adverse reactions in seniors possible, 21

ADVERSE EVENTS *See also* SAFETY

Canada, reporting changes considered, 721
Genetic basis for certain events, FDA releases data, 182
List of drugs posted by FDA, 1202
N.H. reporting bill signed, 921
Ore. reporting system, few pharmacies participating, 950
Orlistat and liver injury, FDA reviews, 1002
Raptiva, FDA issues advisory, 233
Toll-free number on medication guides, FDA issues guidance, 686

ADVERTISING

Aczone ad overstates efficacy, FDA says, 1001
Avodart, FDA says TV ad is misleading, 271
Brazil revises rules, 27
Compliance plans urged, 1110
Depakote, FDA tells maker to pull misleading materials, 159
Efficacy and risk data, FTC seeks comments, 776
Ertaczo ad inaccuracies, FDA warns maker, 1051
GSK plans \$400M charge, federal probe cited, 160
HRT claims, jurisdiction lacking over ad firms with insufficient W.Va. contacts (E.D. Ark.), 367
Humira ad broadens approved indication and minimizes risks, FDA says, 21
Nalfon, FDA warns direct mailer on false or misleading advertising, 1050
Nexium, false advertising class action remanded (3rd Cir.), 587
Promotional materials, FDA pushes accuracy and balance, 1107
Protonix, generic advertising challenged (E.D. Mich.), 554
Risk information
—Draft guidance issued by FDA, 618; stakeholders seek revisions, 999
—Lacking from many Internet ads, 413
Ultram ER web video called misleading by FDA, 623
Velcade maker accused of overstating efficacy, 746
Yaz. *See* YAZ

AFINITOR

Approved for kidney cancer, 383

AIDS AND HIV

Combination drug, In Brief, 871
IDX889 licensing, In Brief, 191
Intelence labels revised due to skin reactions, 1051
IQP-0410, In Brief, 49
Kaletra. *See* KALETRA
Patent infringement, Stanford lacks standing to make claim (Fed. Cir.), 1167
Pricing
—Isentress price cut sought, 892
—Norvir price settlement approved (N.D. Cal.), 942
Selzentry, FDA panel recommends approval, 1206
Specialist firm planned, In Brief, 486

ALABAMA

E-prescribing system announced for Medicaid, 648
Generic drugs, Atty. Gen. seeks to dismiss suits against pharmacies for deceptive trade practices, 1204
Medicaid pricing
—5 firms settle with state (Ala. Cir. Ct.), 40; jury awards \$78.4M (Ala. Cir. Ct.), 227; more firms settle (Ala. Cir. Ct.), 610
—Verdicts reversed (Ala.), 1222

ALDARA

Skin cancer cream blamed for severe symptoms, claim time-barred (D. Utah), 257

ALIMTA

Approved for lung cancer, 809

ALLEGRA

Allergy drug maker tries to block generic (D.N.J.), 119
Infringement alleged over generic (D.N.J.), 1100

ALPHAGAN

Glaucoma drug, generic infringes patent (D. Del.), 1248

AMRIX

Muscle relaxant infringement claim split from antitrust and patent misuse claims (D. Del.), 1192

ANALYSIS & PERSPECTIVE

Calibrating proper dosage for treating certain diseases, method is patentable, 1209
Conflicts of interest, lobbying and gift limits, 1180
De-identified health information and state regulation, 422
Enforcement focused on drug patent settlements, 1006
Exclusivity rule, 979
Federal preemption in drug and device suits, 106
Foreign Corrupt Practices Act compliance, 215
Fraud on agency claims, 1086
Norvir monopoly ruling, 1011
Patents
—Reversing patent settlements, 749
—Risk evaluation and mitigation strategy patents, 28
Phenergan failure to warn claim, 353; effect on preemption defense, 658
Promethazine hydrochloride injection gets boxed warning, 1077
Trademarks, proving use, 52

ANDAs *See* ABBREVIATED NEW DRUG APPLICATIONS (ANDAs)

ANDROGEL

Class actions seek to recoup charges paid due to collusion between brand name and generic firms (C.D. Cal.), 174; transferred to Ga. federal court, 435; N.J. suits transferred (D.N.J.), 670
Testosterone replacement drug, FTC accuses generic and brand name makers colluding to delay (C.D. Cal.), 145

ANTARA

Cholesterol drug, Lupin gets marketing rights (D. Md.), 1194

ANTI-KICKBACK LAWS

UN Oil for Food Program, Danish firm settles charges (D.D.C.), 558

ANTIBIOTICS

Cephem compound double patent challenge, summary judgment vacated (Fed. Cir.), 433
Doryx. *See* DORYX
Flucloxacillin associated with liver damage, 652
HGS and Morphotek, In Brief, 386
Leaquin blamed for tendon rupture (D. Minn.), 1170
Plectasin NZZ114, In Brief, 25
R&D
—Biogen and Aveo, In Brief, 386
—Paratek and Novartis, In Brief, 1208
Restanza, In Brief, 1084
Trovan maker accused of violating international norms (2nd Cir.), 147

ANTIDEPRESSANTS

Celexa competing patents, two claims invalidated by prior art (S.D.N.Y.), 673; jury awards royalty, 1247
Consolidation of product liability claims denied (D. Mo.), 639
Effexor. *See* EFFEXOR
Failure-to-warn of suicide risk, preemption ruling remanded (U.S.), 280; vacated and remanded (3rd Cir.), 497; briefs filed, 498
Labopharm, In Brief, 871
Lexapro. *See* LEXAPRO
Paxil. *See* PAXIL

ANTIDEPRESSANTS —Contd.
Wellbutrin. *See* WELLBUTRIN

ANTITRUST

Amrix infringement claim split from antitrust and patent misuse claims (D. Del.), 1192
AndroGel, class actions seek to recoup charges paid due to collusion between brand name and generic firms (C.D. Cal.), 174; transferred to Ga. federal court, 435; N.J. suits transferred (D.N.J.), 670
Apotex counterclaims against Daiichi dismissed (D.N.J.), 636
Arava generic, jury verdict against maker upheld (S.D.N.Y.), 1023
BMS to settle with states over court order violations, 12
Cipro. *See* CIPRO
Community Medical suit against drug maker over price may proceed (D. Minn.), 1218
CVS Caremark merger, FTC probe sought, 565; pharmacists group alleges monopoly, 565
EU, drug firm seeks exemption, 1179
False statements, former exec ordered to write book about case (D.D.C.), 679
Hytrin monopoly claim remanded (9th Cir.), 91
K-Dur purchasers class certified (D.N.J.), 38; special master recommends dropping, 175
Leibowitz as FTC chair, more scrutiny predicted for drug industry, 261
McKesson settles price inflation claims (D. Mass.), 909
Mergers. *See* MERGERS AND ACQUISITIONS
Neurotonin, monopoly claim against maker may proceed (D.N.J.), 1026
Nifedipine direct purchasers class action certified (D.C. Cir.), 229
Norvir maker cleared of monopoly charges (9th Cir.), 791; rehearing denied, 987; Analysis & Perspective, 1011
Ovcon settlement reached (D.D.C.), 12
Plavix suit, former executive pleads guilty to false statements (D.D.C.), 401
Reverse payment deals
—Position of Obama administration sought, 476
—Targeted by FTC, 372
RxUSA monopoly claim rejected (E.D.N.Y.), 1132
Singulair class action voluntarily dismissed (D.N.J.), 1099
Transferor judge's ruling cannot be vacated (3rd Cir.), 1134
Transparency
—Pushed at Senate panel, 862
Tricor, consumer suit over generic delay, settlement approved (D. Del.), 500
Unenforceable patents, direct buyer plaintiffs have standing (2nd Cir.), 1217
Unlawful conspiracy claims, transferor judge's ruling cannot be vacated (3rd Cir.), 1134
Videotaping testimony by FTC permitted (D.C. Cir.), 1253
Wellbutrin, direct purchaser antitrust suit may proceed (E.D. Pa.), 308

APPLICATIONS

Acetavance, In Brief, 596
Acurox, In Brief, 51; expedited review, In Brief, 272; preliminary review letter, In Brief, 747; review continues, 811
Afresa, In Brief, 324; new application, In Brief, 595
Alogliptin and Actos combo, In Brief, 1053
AM461, In Brief, 978
ANDAs. *See* ABBREVIATED NEW DRUG APPLICATIONS (ANDAs)
AR-12, In Brief, 570
AR-42, In Brief, 324
Aricept, new drug application planned, 808
Arzerra, In Brief, 164; called safe and effective by FDA panel, 649; review extended, In Brief, 720
Aspirin-ulcer drug combo, In Brief, 541
Asthma drug combo, In Brief, 896
Avodart, In Brief, 1178

Bepreve, In Brief, 105
Botox, In Brief, 626
Carisbamate, In Brief, 1005
Cefazolin, In Brief, 655
Ceftobiprole, In Brief, 1055
Certriad, In Brief, 692
Cervarix. *See* CERVARIX
Ciltryi, In Brief, 1117
Cimzia, FDA wants more data, 46
Cinryze. *See* CINRYZE
Cladrinbine, In Brief, 1149
Clolar, more data sought, 1176
Colitis drug, FDA wants more data, 46
CorVue, FDA panel says data insufficient, 892
CorVue, In Brief, 1237
Cymbalta, In Brief, 655
Dantrium IV, In Brief, 1149
Daxas, In Brief, 871
Denosumab, In Brief, 24
Diabetes drug combo, In Brief, 896
Diabetes treatment, FDA to apply guidance, 295
Durezol, In Brief, 324
DX-88, In Brief, 385
EOquin, In Brief, 872
Erbix, In Brief, 134
Exenatide, In Brief, 541; 811
Fampridine-SR, In Brief, 385; 571
Fenretinide, In Brief, 450
Flutiform. *See* FLUTIFORM
Fortesta, In Brief, 1237
Fusilev, In Brief, 1208
Ganciclovir ophthalmic gel, In Brief, 134
Genasense, In Brief, 297
GGTI-2418, In Brief, 192; 271
Imitrex, In Brief, 213
Intelence, In Brief, 192
Intermezzo, FDA wants more data, 1263
Intermezzo, In Brief, 719
Intuniv, In Brief, 895
Invega, In Brief, 191
Isolagen Therapy, In Brief, 298
Krystexxa, In Brief, 1084
LiquiXR, In Brief, 570
Loramyc, In Brief, 720
Lucassin, In Brief, 719
Lumizyme, FDA seeks more information, 270
MGX006, In Brief, 838
Micardis, In Brief, 1237
Miconazole Lauriad, In Brief, 977
MonoSol XR, In Brief, 451
Nebido, In Brief, 1054
Nexium, In Brief, 25
NGX-4019, In Brief, 25
Nonsteroidal anti-inflammatory drug, 418
Nuvigil, In Brief, 1150
Ondansetron ODFS, In Brief, 691
Onglyza timeline extended, 513
OnoGenex, In Brief, 1178
Ongrin, In Brief, 212; application accepted, 486
Pegloticase, In Brief, 51
PEGylated interferon beta-1a, In Brief, 838
Pennsaid, In Brief, 926
Perceiva, In Brief, 1237
Pixantrone, In Brief, 134; rolling submission, In Brief, 451; priority review sought, In Brief, 747; NDA accepted, In Brief, 1005; action date, In Brief, 1053
PN 400, In Brief, 596
PolyHeme not approved, In Brief, 542
Prevnar 13, In Brief, 952
prGCD, In Brief, 1004
Prolia, In Brief, 1237
Provence application planned, 1147
QAB149, In Brief, 1237
Qutenza, In Brief, 953
Reloxin, In Brief, 78
Remoxy, In Brief, 811
Replagal maker plans license application, 1236
Restanza called safe, but not effective by FDA panel, 649
Retigabine, In Brief, 1116

Rexin-G, In Brief, 720
Rezonic, In Brief, 747; 1150
Rispedal, In Brief, 213
Rituxan, In Brief, 595
ROX-888, In Brief, 192
Saphris, In Brief, 105; 238; 927
Seroquel XR, In Brief, 24
Stelara, In Brief, 626
Sunitinib, In Brief, 595
Surfaxin, FDA wants more data, 477
Surfaxin, In Brief, 1085
Symbicort, In Brief, 418
Tarceva, In Brief, 352
Trelstar, In Brief, 838
Twynsta, In Brief, 1237
Tykerb, In Brief, 384
Tyvaso, In Brief, 324; 515
Ustekinumab, In Brief, 25
Velaglucerase alfa, In Brief, 811
Vimovo, In Brief, 812; 1055
Xarelto makers plan to respond to FDA, 866
Xiaflex, In Brief, 515
XPI2B, In Brief, 419
Zegerid, In Brief, 164
Zenpep, In Brief, 747
Zevalin, In Brief, 811
Zogenix, In Brief, 212
Zyprexa, In Brief, 78

APPROVALS

ACTOplus met, In Brief, 569
Acuvail, In Brief, 896
Adcirca, In Brief, 626
Alimta approved for lung cancer, 809
Apidra SoloSTAR, In Brief, 272
Arzerra approved, 1262
Astepro, In Brief, 1054
Atryp approved by FDA, 190
Avastin. *See* AVASTIN
Average approval time down at FDA, development time up, 74
Axert, In Brief, 692
Azor, In Brief, 570
Bepreve. *See* BEPREVE
Berinert approved, 1207
Besivance approved, 651
Cervarix cleared by FDA panel, 1234
Cimzia, In Brief, 596
CIP-Tramadol ER, In Brief, 212
Citizen petitions, FDA issues draft guide, 122
Coartem tablets approved for malaria infections, 416
Colcrya approved, 923
Creon, In Brief, 541
DaTSCAN, FDA panel recommends approval, 951
Degarelix approved, 22
DX-88, FDA panel favors approval, 188
Effient approved, 836
Elitek, In Brief, 1238
Embeda, In Brief, 978
Extavia, In Brief, 978
Fampridine cleared by FDA panel, 1235
Fanapt approved for adult schizophrenia with warning, 539
Feraheme, In Brief, 812
Folotylin, approved for lymphoma, 1146
Forteo, In Brief, 896
Gelnique, In Brief, 134
Generics. *See* GENERIC DRUGS
Gleevec approved, 23
Helixate FS, 978
Heparin, In Brief, 1055
Hiberix gets accelerated approval, 1002
Ibuprofen Injectable dosage approved by FDA, 717
Illaris, In Brief, 748
Invega Sustenna, In Brief, 927
Kapixid, In Brief, 164
Kogenate FS, In Brief, 953
Krystexxa, In Brief, 719; 927
Labopharm, In Brief, 871
Lamictal XR, In Brief, 656

APPROVALS—Contd.

Lexapro approved for adolescents, 350
Livalo approved, 923
Metozolv ODT, In Brief, 1085
Mirena approved by FDA, 1177
Multaq. *See* MULTAQ
Nexterone, In Brief, 50
Onglyza approved, 922
Onglyza, FDA panel favors approval, 414
Pegintron cleared by FDA panel, 1176
Prasugrel, FDA panel favors approval, 159; consumer group opposes, 649
Prolastin, In Brief, 1237
Prolia approval recommended by FDA panel, 808
Provenge, politically-motivated delay in approval alleged, dismissal affirmed (U.S., rev den), 61
Reclast, In Brief, 656
RiaSTAP approved for bleeding in patients with congenital fibrinogen deficiency, 102
Rituxan, In Brief, 1237
Rivaroxaban gets favorable review from FDA panel, 351; gets complete response letter, 650
Robinul, In Brief, 1005
Romidepsin approval urged by FDA panel, 1050
Romidepsin, FDA panel favors approval, 1050
Ryzolt, In Brief, 51
Sabril cleared by FDA panel, 73; approved for adult seizures, 1003
Samsca, In Brief, 627
Sanvar, In Brief, 627
Saphris, In Brief, 978
Savella, In Brief, 105
Selzentry, FDA panel recommends approval, 1206
Silenor application rejected by FDA, 446
Simponi for arthritis, 513
Stelara approved, 1146
Surfaxom, In Brief, 812
Symbicort, In Brief, 272
Symbyax, In Brief, 352
Tekturna HCT, In Brief, 871
Topamax, In Brief, 1238
Tygacil, In Brief, 352
Tyvaso approved, 923
Uloric, In Brief, 212
Valturna, In Brief, 1117
Vancomycin, In Brief, 570
Vectical, In Brief, 163
Votrient cleared by FDA panel, 1176; approved, 1235
Welchol, In Brief, 1208
Xiaflex, FDA panel urges approval, 1113
Zenpep approved by FDA, 1052
Zingo, In Brief, 77
Zipsor, In Brief, 748
Zirgan, In Brief, 1084
Zolpimist, In Brief, 24
Zyprexa, In Brief, 352

ARANESP

Anemia drug illegal marketing alleged (D. Mass.), 255
Off-label promotion
—Class action dismissed (C.D. Cal.), 730
—RICO does not apply (C.D. Cal.), 37

ARAVA

Arthritis drug antitrust suit, jury verdict against maker upheld (S.D.N.Y.), 1023

ARBITRATION

Remicide distribution agreement, arbitration sought, 622

AREDIA

Biophosphonates blamed for osteoporosis, summary judgment denied (M.D. Tenn.), 995

ARICEPT

Alzheimer's drug infringement alleged, inequitable conduct defense permitted (D.N.J.), 796
New drug application planned, 808

ARZERRA

Leukemia drug, In Brief, 164; called safe and effective by FDA panel, 649; approved, 1262

ATRYN

Anticoagulant approved by FDA, 190

ATTORNEYS

Falsified drug paperwork (D.N.H.), In Brief, 617
Fen-phen settlement, attorneys convicted of bilking plaintiffs (E.D. Ky.), 467

ATTORNEYS' FEES

Actos patent dispute, attorneys' fees upheld (U.S., rev den), 1166
Fen-phen, fee award for attorneys affirmed (3rd Cir.), 1226

AVANDIA

Diabetes drug product liability, sales rep properly joined (E.D. Pa.), 826
Failure-to-warn suits remanded (E.D. Pa.), 284
Investors' security fraud suit dismissed (S.D.N.Y.), 992
Public Citizen wants ban, 866

AVASTIN

Brain cancer treatment, FDA panel favors approval, 381; approved, 540
CalPERS approves for ovarian cancer, 296
Kidney cancer, In Brief, 927

AVINZA

Pain drug, infringement alleged over generic ANDA (D.N.J.), 1071

AVODART

Prostate treatment, FDA says TV ad is misleading, 271

AZOPT

Eye drug maker alleges infringement (E.D. Tex.), 119

AZOR

Blood pressure drug, generic ANDAs infringe patent (D.N.J.), 938; appeal filed, 991

B

BANKRUPTCY

Biopure files Ch. 11, 893
Oscient files Ch. 11, 893

BCBS *See* BLUE CROSS AND BLUE SHIELD PLANS (BCBS)

BENICAR

Blood pressure drug, generic ANDAs infringe patent (D.N.J.), 938

BEPREVE

Application, In Brief, 105
Ocular itching drug cleared by FDA panel, 781; approved, In Brief, 1238

BERINERT

Angioedema drug approved, 1207

BESIVANCE

Bacterial conjunctivitis drug approved, 651

BEXTRA

Arthritis drug trade secrets, Pfizer must pay \$38M to research firm (Cal. Super.), 11
Consumer fraud and injury class action settlement gets preliminary approval (N.D. Cal.), 339; approved, 1225
Illegal marketing, Pfizer fined \$1.2B, 1047; sentenced, In Brief, 1238
Off-label marketing
—Ex-sales manager pleads guilty (D. Mass.), 370; sentenced, 736

BIOGENERIC

Approval pathway sought by firm, 186; AARP seeks, 290; would cut costs, FTC says, 681; CareFirst supports, 690; MedPAC reports, 710; House debate to continue, 713; Senate panel debates, 801; House panel's pathway includes 12 years of data exclusivity, 831
Cost containment and generics examined by CBO, 16
Hatch (R-Utah) pushes, 288
Health reform. *See* LEGISLATION, FEDERAL, HR 3200
Legal outlook 2009, 79
License revocations, FDA issues notification rule, 532
Marketing, In Brief, 1208
Regulatory outlook 2009, 80
Waxman (D-Cal) pushes, 686

BIOLOGICS

Approval pathway for generics sought, 186
Arzerra, In Brief, 720
Atryn approved by FDA, 190
Cimzia. *See* CIMZIA
Cinryze. *See* CINRYZE
Consensus sought on generic biologics, 235
Data exclusivity, 12 years called too long, 1205
Delays in regulatory review, advice offered, 1078
Denosumab, In Brief, 212
Erbix. *See* ERBITUX
Exclusivity, White House calls for 7 years, 772
Generics, In Brief, 782
GSK and Dynavax, In Brief, 26
Merck follow-on platform, In Brief, 213
Plant shut down, 718; to reopen, 869
PolyHeme maker shuts down, 594
Quality, new analytical methods and standards urged at House hearing, 1143
R&D deal, In Brief, 811
Replagal maker plans license application, 1236

BIRTH CONTROL *See* CONTRACEPTION

BLOOD PRODUCTS

PolyHeme maker shuts down, 594
Taiwanese hemophiliacs claims against concentrate makers time-barred (N.D. Ill.), 466

BLUE CROSS AND BLUE SHIELD PLANS (BCBS)

Generic drugs, community-based programs expanding use, 450

BOTOX

Off-label promotions, maker seeks to block FDA enforcement (D.D.C.), 1163

BOX WARNINGS *See* LABELS AND PACKAGING

BRAZIL

Advertising rules revised, 27
Domestic equivalents to replace drug imports, 487
Patents, pipeline law challenged, 597
Price hikes authorized, 387

BUDGET, U.S. *See* specific agencies and departments

FY2010. *See* LEGISLATION, FEDERAL, SConRes 13

C

CABILLY II

Antibody production patent, PTO confirms claims of validity, 270

CALIFORNIA

Medi-Cal cuts challenged by pharmacists (C.D. Cal.), 151; cuts enjoined, 256; hospital and pharmacy reimbursement cuts blocked (9th Cir.), 404

CALIFORNIA —Contd.

Overtime for drug firm sales reps, guidance sought from Cal. court (9th Cir.), 555
Pricing, counties denied class certification in suit against drug firms (N.D. Cal.), 611
State and local government employees
—Avastin, CalPERS approves for ovarian cancer, 296
—E-prescriptions, CalPERS plans pilot project, 348

CAMPATH

MS drug, Genzyme buys rights, 384

CANADA

Adverse event reporting changes considered, 721
Fanapt, In Brief, 1208
Market exclusivity rules upheld (Fed. Ct.), 897
Nicoderm pricing hearing, challenge rejected, 1239
Norvasc patent invalidated, 839; reasons released, 1057
Pricing
—Average drug price calculation, decision on rebates and discounts rejected (Fed. Ct.), 898
—Increase reported for 2008, 928

CANCER

Afinitor approved for kidney cancer, 383
Alimta approved for lung cancer, 809
Antibody license, In Brief, 1265
Antitumoral agent, In Brief, 191
AR-12, In Brief, 570
AR-42, In Brief, 324
Arzerra called safe and effective by FDA panel, 649
AT-406, In Brief, 1085
Avastin. *See* AVASTIN
Cervarix. *See* CERVARIX
Cervarix cleared by FDA panel, 1234
Clolar application, more data sought, 1176
Clolar, more trials urged by FDA panel, 1049
Combination drugs. *See* COMBINATION DRUGS
Combination drugs, In Brief, 571
Debio 0928, In Brief, 748
DI-Leu 16-IL2 license, In Brief, 323
DTS-108, In Brief, 25
Elesclomol, In Brief, 720
Eloxatin. *See* ELOXATIN
EOquin, In Brief, 872
Erbbitux. *See* ERBITUX
Ethylol patent dispute settled (D. Md.), 910
Firmagon, In Brief, 926
Folotylin, FDA panel reports clinical benefit, 1049; approved, 1146
Gardasil. *See* GARDASIL
Genzer, method-of-use patent invalid (E.D. Mich.), 962
Gleevec approved, 23
GSK and Oxford collaboration, In Brief, 595
Joint venture to sell cancer drugs, \$3M award for negligent misrepresentation (5th Cir.), 799
Lantus, FDA examines cancer risk, 809
Liraglutide cancer risk disputed, 414
MDV3100, In Brief, 324; marketing, In Brief, 1265
MDX-1203, In Brief, 164
MDX-1338, In Brief, 626
Medicare contractor to cover off-label use for ovarian cancer treatment, 471
MM-121, In Brief, 1178
MORAb-004, In Brief, 691
New drugs, 861 in development, 383
Off-label drug studies vary in quality, 1258
OncoVex, In Brief, 1084
(131)I-CLR1404, In Brief, 272
Onsolsis approved, 867
Paclical, In Brief, 451
Pegintron cleared by FDA panel, 1176
PLK-1, In Brief, 570
Rexin-G, In Brief, 720
Romidepsin approval urged by FDA panel, 1050
Sunitinib, In Brief, 595
TNF blockers risk, FDA requires stronger warning, 918

Treanda patients, skin reaction reported, 513
TRU-016, In Brief, 1055
Valstar, In Brief, 1054
Votrient cleared by FDA panel, 1176
Xeloda, generic challenged (D.N.J.), 438
Zometa. *See* ZOMETA

CARBATROL

Seizure drug generic challenge settled (S.D.N.Y.), 1100

CARDENE

Cardiac drug, generic ANDA challenged (D.N.J.), 401

CARDIZEM

Blood pressure drug, firm pleads guilty to illegal marketing (D. Mass.), 1067

CARVEDILOL

Congestive heart failure treatment, infringement claim settled (D.N.J.), 587

CEFTAROLINE

Anti-effective in development, 977

CELEBREX

Consumer fraud and injury class action settlement gets preliminary approval (N.D. Cal.), 339; approved, 1225

CELEXA

Antidepressant competing patents, two claims invalidated by prior art (S.D.N.Y.), 673; jury awards royalty, 1247

CELLCEPT

Anemia risk, maker warns providers, 976
Miscarriage risk, FDA requires medication guide with prescriptions, 210

CEPHALON

Narcolepsy drug off-label use, class action dismissed (D.N.J.), 1196

CERVARIX

Cervical cancer vaccine endorsed by FDA panel, 1083; review continues, In Brief, 1149
Efficacy study, In Brief, 385
HPV vaccine cleared by FDA panel, 1234

CHANTIX

Consolidation of product liability suits ordered (N.D. Ala., S.D. Ill.), 1169
Construction/compensation defect, inadequate warning, and warrant breach claims may proceed (W.D. La.), 1198
Risks downplayed, suit alleges (D. Minn.), 944
Smoking cessation drug blamed for violent episodes and resulting death (N.D. Tex.), 1072
Wrongful death suit, breach of warranty claim may proceed (S.D. Ind.), 178

CHILDREN'S HEALTH CARE

ADHD drugs tied to cardiac deaths, FDA reports, 714
Identifying knowledge gaps on drugs and children, NIH plans program, 443
Off-label use of pediatric products, Special Report, 572

CIMZIA

Arthritis drug, FDA wants more data before approval, 46
Licensing, In Brief, 191

CINRYZE

Angioedema treatment gets priority review, 163; FDA seeks more data, 690

CIPRO

Antitrust

—Generic, agreement blocking upheld (Cal. Sup. Ct.), 987

—Settlement challenged (U.S., rev den), 730
Reverse payments in patent settlements, DOJ files brief (2nd Cir.), 790

CLARINEX

Allergy drug patent suit settled (D.N.J.), 437
Generic permitted (D.N.J.), 943

CLASS ACTIONS

AndroGel, suits seek to recoup charges paid due to collusion between brand name and generic firms (C.D. Cal.), 174; transferred to Ga. federal court, 435
Bextra/Celebrex consumer fraud and injury class action settlement gets preliminary approval (N.D. Cal.), 339
Cal. counties denied class certification in pricing suit against drug firms (N.D. Cal.), 611
K-Dur purchasers class certified (D.N.J.), 38; special master recommends dropping, 175
Merck employees class action over alleged artificially inflated stock certified (D.N.J.), 204
Neurotonin. *See* NEUROTONIN
Nexium, false advertising class action remanded (3rd Cir.), 587
Nifedipine direct purchasers antitrust class action certified (D.C. Cir.), 229
Off-label use. *See* OFF-LABEL USE
Prilosec, maker accused of failure to warn of food poisoning risk (S.D. Ohio), 680
Securities. *See* SECURITIES
Singular class action voluntarily dismissed (D.N.J.), 1099
Stiefel accused of undervaluing stock in buy-back scheme (S.D. Fla.), 828
Trasylol, RICO suit against surgery drug maker dismissed (S.D. Fla.), 965
Vioxx. *See* VIOXX
Viread maker accused of misrepresenting sales (N.D. Cal.), 679; some shareholder claims may proceed, 1229
Wellbutrin, generic makers accused of making inferior product (Cal. Super. Ct.), 706
Zyprexa overpayments, class certification for third party payers granted (2nd Cir.), 152

CLINICAL TRIALS *See also* HUMAN SUBJECT PROTECTION; RESEARCH AND DEVELOPMENT (R&D)

Antitumoral agent, In Brief, 191
AT-406, In Brief, 1085
ATPace, In Brief, 212; design approved, In Brief, 655
Billing audit and monitoring conference planned by BNA, In Brief, 76
BNA plans conference, In Brief, 48
CD-NP, In Brief, 596
Certification, FDA issues final guidance, 124
Clolar, more trials urged by FDA panel, 1049
CM-AT, In Brief, 352
CollaRx Bupivacaine Implant clinical trial enjoined (E.D. Pa.), 149
Contract research organizations addressed at BNA audioconference, 477
DP-b99, In Brief, 692
Esreboxetine, In Brief, 237
Experimental treatments
—Seriously ill patients, FDA issues access rules, 946
Fibromyalgia, In Brief, 237
Financial disclosures, HHS IG criticizes FDA oversight, 66
Good Clinical Practices Initiative, FDA reaches agreement with EU agency, 919
Investigator may be criminally liable for not following FDA reporting requirements (5th Cir.), 175
IQP-0410, In Brief, 49
J&J trials under FDA scrutiny, 975
KRX-0401, In Brief, 926
MDV3100, In Brief, 324

CLINICAL TRIALS—Contd.

MDX-1203, In Brief, 164
MDX-1338, In Brief, 626
Minn. psychiatric clinical trial limits, bill signed, 593
MORAb-004, In Brief, 691
MoxDuo IR, In Brief, 239
OncoVex, In Brief, 1084
(131)I-CLR1404, In Brief, 272
Payments to providers and institutions, GSK to disclosure, 382
PD 332,334, In Brief, 237
PLK-1, In Brief, 570
Post-marketing studies
—Draft guidance issued by FDA, 862
—Oversight at FDA, GAO reports, 1258
—Timetables met by most firms, FDA reports, 1043
Principles for conducting trials released by PhRMA, 1112
Registries use up, reporting requirements of journals and agencies cited, 410
Review by HHS IG, In Brief, 1175
Stem cell ALS trial, In Brief, 26
Syncra, In Brief, 212
VIA-2291, In Brief, 719
Warfarin, Medicare to cover clinical trial, 946
Website seeks to improve participation, 977

CLOBEL

Psoriasis drug patent infringement alleged (N.D. Tex.), 63

COLLAR

Leukemia drug application, more data sought, 1176
Leukemia drug, more trials urged by FDA panel, 1049

COARTEM

Approved for malaria infections, 416

COLCHICINE

Gout drug not enjoined (C.D. Cal.), 1249

COLCRYA

Gout drug approved, 923

COLLARX BUIVACAINE IMPLANT

Pain relief, combination drug clinical trial enjoined (E.D. Pa.), 149

COLLEGES AND UNIVERSITIES

Ferris State Univ. sued by labor coalition, drug plan data sought (Mich. Cir. Ct.), 283
Grassley (R-Iowa) wants conflict of interest disclosures by med schools, 741
Harvard Medical School to revise conflicts of interest policy, 161
Stanford
—AIDS therapy, school lacks standing to make infringement claim (Fed. Cir.), 1167
—Med school to post MD-industry ties, 416
Univ. of Iowa proposes new conflicts of interest policy, 160

COMBIGAN

Glaucoma drug, generic challenged (E.D. Tex.), 438

COMBINATION DRUGS

AIDS, In Brief, 871
Alogliptin and Actos combo, In Brief, 1053
Asthma, In Brief, 896
Cancer
—Anticancer combo, In Brief, 656
—AstraZeneca and Merck, In Brief, 656
—CombinatoRX and Novartis alliance, In Brief, 571
—Doxil and trabectedin do not have good benefit to risk profile, FDA panel says, 867
CollaRx Bupivacaine Implant clinical trial enjoined (E.D. Pa.), 149
Communication between FDA and makers urged, 409
Diabetes, In Brief, 896
Diet drug blamed for death (E.D. Pa.), 438

Guidance on clinical trials sought by industry, 651
Industry practices, FDA proposes rule, 1106
Injection devices, FDA issues draft guidance, 506
LTX-315 and GV1001, In Brief, 747
Safety rule proposed by FDA, 1173

COMPARATIVE EFFECTIVENESS

AHRQ use of funds at issue, 411; agency will expand pre-existing research, 924
Baucus (D-Mont) and Grassley (R-Iowa) offer policy options, 503; Baucus say no rationing of care, 684
Coelho to lead research group, 322
Commonwealth Fund supports research, 211
Cost savings questioned, 1052
Data infrastructure, coordinating panel urges funding, 775
Discussed at conference, 712
Examined by CBO, 16
Fact sheet issued by Kaiser, 1177
GOP senators drafting proposal, 711
Health reform with comparative effectiveness will give providers more control over treatment decision, report says, 449; comparative effectiveness called essential to reform, 1114
HELP panel releases draft Senate bill, 683; markup, 739
Innovation as focus urged for lawmakers, 483
Institute of Medicine reports, 774
Labels, FDA urged to include effectiveness data, 1148
Lewin Group announce research center, 869
“Listening session,” federal panel hears concerns, 441; panel holds second session, 591; patent-focused research urged, 684
Medicare, use of comparative effectiveness research urged, 104
Patient-centered solutions pushed, 75
Savings and improved outcomes called key, 103; systems in other nations studied, 625
Stimulus bill. *See* LEGISLATION, FEDERAL, HR 1, S 1
Supported by health care leaders, 895

CONCERTA

ADHD drug, generic no infringement (D. Del.), 364

CONFERENCES AND MEETINGS

American Bar Ass'n Antitrust Law Section, 372
American Health Lawyers Ass'n
—Annual Meeting, 779; 807
American Intellectual Property Law Ass'n, Mid-Winter Institute, 186
BIO 2009, 622; 654
BNA, “Planning for a Post *Levine* World: Implications and Strategies for Manufacturers, U.S. Consumers and the Courts,” 564
Center for Business Intelligence, 745
Food and Drug Law Institute, 1110
—Annual Conf., 504
Generic Pharmaceutical Ass'n, 1077
—Annual meeting, 235
Natl. Pharmaceutical Council and the Personalized Medicine Coalition, 1264
Natl. Pharmaceutical Council, Entering a New Era of Evidence, 712
Pharmaceutical Care Management Ass'n, 1205
Regulatory Affairs Professional Society, 1000; 1078; 1078
U.S. Chamber of Commerce, 103; 104

CONFLICT OF INTERESTS

Medical education funding, GSK limits, 1113

CONFLICTS OF INTEREST

Association formed to defend industry ties to providers, 892
Clinical trials, payments to providers and institutions, GSK to disclosure, 382
Forest Labs payment to Minn. MDs reported, 1080

Ghostwriting policies

—HRT suit, discovery documents unsealed (E.D. Ark.), 915
Gifts to MDs. *See* PHYSICIANS
Grassley (R-Iowa) wants disclosures by med schools, 741; seeks information on Natl. Alliance for Mental Illness, 1257
Lobbying and gift limits, Analysis & Perspective, 1180
Massachusetts
—Fees for covered firms due Jul. 1, 648
—Hospital network to limit interaction with industry, 441
Medicare compendia, conflicts of interest seen as inherent, 625
Physicians. *See* PHYSICIANS
Univ. of Iowa proposes new policy, 160

CONGRESS, U.S.

Ed. Note: This heading is used for administrative actions only. For coverage of legislation by bill number, see LEGISLATION, FEDERAL. For information on measures not yet assigned bill numbers see specific subject headings.
Hill Watch, In Brief, 452

CONNECTICUT

Gifts to MDs, ban urged, 293

CONTAN

Parkinson's drug infringement claims settled (D. Del.), 526

CONTRACEPTION

Loestrin 24, generic sales opposed (D. Del.), 1068
Mircette, In Brief, 51
Nuvaring, defendants barred from conducting ex parte interviews with treating MDs (E.D. Mo.), 367
Ortho Tri-Cyclen maker challenges generic (D.N.J.), 733; generic maker halts shipments, 836; settled, 879
Plan B
—Generic by Duramed approved, 741; Watson generic approved, 1055
—Ill. dispensing requirement challenged by pharmacists (Ill.), 7
—One-Step, In Brief, 837
—OTC limits by FDA restrictions arbitrary (E.D.N.Y.), 334
—Wash. dispensing requirement, injunction vacated (9th Cir.), 823
RU-486, prescribing for off-label use banned (Ohio), 794; remanded (6th Cir.), 943
Yasmin. *See* YASMIN
Yaz. *See* YAZ

CORVUE

Vasodilator drug, FDA panel says data insufficient, 892

COSOPT

Glaucoma drug, FDA exclusivity ruling upheld, 8

COST CONTAINMENT

Biogenerics examined by CBO, 16
Children's hospitals buy low cost drugs through HRSA, 1044
Comparative effectiveness. *See* COMPARATIVE EFFECTIVENESS
Sebelius wants to look at all options, 440
Trends
—Forecast for 2010 released, 1004
—Generic use slows drug spending, CMS says, 42; savings over decade reported, 567; limited spending growth, 567
—Sales growth slowed in 2008, 350

COUNTERFEIT DRUGS

Criminal penalties. *See* LEGISLATION, FEDERAL, HR 1450
Draft guidance issued by FDA, 835

CRIMINAL PROSECUTION *See also* FRAUD AND ABUSE

Acquiring controlled substances by deception (W.D. Wash.), In Brief, 286
Bextra illegal marketing, Pfizer fined \$1.2B, 1047
Cardizem maker pleads guilty to illegal marketing (D. Mass.), 1067
Clinical investigator may be criminally liable for not following FDA reporting requirements (5th Cir.), 175
Counterfeit drugs. *See* LEGISLATION, FEDERAL, HR 1450
False statements, former exec ordered to write book about case (D.D.C.), 679
Falsified drug paperwork (D.N.H.), In Brief, 617
InterMune CEO guilty of wire fraud (N.D. Cal.), 1164
Internet pharmacy (E.D. Mo.), In Brief, 972
Off-label use
—Actimmune off-label uses, indictment of CEO upheld (N.D. Cal.), 675
—Bextra marketing, ex-sales manager pleads guilty (D. Mass.), 370; sentenced, 736
—Destruction of documents, ex-manager convicted of obstruction of justice (D. Mass.), 316; sentenced, 885
“Pill mill,” pharmacist convicted (Kan. Dist. Ct.), 617
Plavix suit, former executive pleads guilty to false statements (D.D.C.), 401
Smuggling unapproved cancer drugs (C.D. Cal.), In Brief, 558

D**DATA MINING**

N.H. ban on prescription data sales upheld (U.S., rev sought), 363; other states await ruling, 544; (rev den), 763
Vt. ban on sale of prescription data by MDs upheld (D. Vt.), 495; firms denied injunction, 670

DaTSCAN

Radiopharmaceutical agent, FDA panel recommends approval, 951

DEGARELIX

Prostate cancer drug approved, 22

DELAWARE

Medicaid, Omnicare to settle overcharging claims, 638

DEPAKOTE

Epilepsy drug, FDA tells maker to pull misleading advertising, 159
Generic approved, In Brief, 164

DETROL

Bladder drug maker did not mislead PTO in prosecuting patent (D.N.J.), 461; discovery of marketing documents denied, 701

DIET DRUGS *See* WEIGHT LOSS PRODUCTS AND PROGRAMS**DIGITEK**

Failure-to-warn claims may proceed (S.D. W.Va.), 993
Heart attack death blamed on heart drug (E.D. Tex.), 502
Product liability suits consolidated (Tex.), 944

DISCOUNTS

Marketing claims settled (Pa. Commw. Ct.), 179
Medicare, gap in coverage, drug makers promise discounts for some enrollees, 744
N.Y. launches low-income drug card plan, 348
PAP, In Brief, 978

DISTRICT OF COLUMBIA

PBM disclosure law preempted (D.D.C.), 333

DORYX

Acne drug maker seeks to block generic (D. N.J.), 336
Antibiotic, generic ANDAs challenged as infringement, 14

DUAC

Acne cream maker claims infringement by generic (D. Del.), 640

DURAGESIC

Pain patch lots recalled, 46

DX-88

Hereditary angioedema drug, FDA panel favors approval, 188

E**E-HEALTH**

Electronic prescriptions. *See* E-PRESCRIPTIONS
Incentives for MDs, new law studied, 322
N.M. considers requiring notification of E-health breaches, 184

E-PRESCRIPTIONS

AMA launches online learning center, 384
DrFirst to offer through AMA platform, 484
Incentives sought by community pharmacists, 482
Medicare. *See* MEDICARE DRUG COVERAGE
Regulatory outlook 2009, 80
State developments
—Ala. Medicaid system announced, 648
—CalPERS plans pilot project, 348
—Governors' group examines, 894
—Iowa promotes for MDs, 1236
—Mass. leads states for third year, 746
Usage reported, 514
Wider adoption pushed by feds, 1115

EFFEXOR

Antidepressant blamed for suicide, jury verdict for drug maker upheld (7th Cir.), 230
Generics
—Challenged (D. Del.), 437
—Infringement claimed (D. Del.), 63
—Summary judgment denied (N.D. W.Va.), 1219

EFFIENT

Blood clot drug approved, 836; in pharmacies, 926

EFUZEZ

Dermatological drug, investment firm accused of giving trade secrets to competitor (D. Del.), 523

ELIDEL

Skin care cream blamed for cancer, suits remanded (D.N.J.), 734

ELOXATIN

Cancer drug approved, In Brief, 952; approval suspended, 963; approval reinstated, 1001
Proposed generics no infringement (D.N.J.), 732; stay denied, 822; infringement ruling vacated (Fed. Cir.), 1065; settlement upheld, 1193

EMBEDA

Pain drug videos, FDA says risks omitted or minimized, 1235

EMEND

Anti-nausea drug, generic plans challenged (D.N.J.), 284

ENBREL

Arthritis drug maker accused of illegal marketing (D. Mass.), 255
Non-infringement ruling affirmed (Fed. Cir.), 635

ENFORCEMENT POLICY

Clinical trials, HHS IG to review, In Brief, 1175

Federal Register format changed, 1174

EPOGEN

Anemia drug off-label promotion, RICO does not apply (C.D. Cal.), 37

ERBITUX

Cancer drug, FDA wants additional study for first-line squamous cell carcinoma of the head and neck, 270
Label revision approved by FDA, 870

ERECTILE DYSFUNCTION DRUGS

Levitra generic challenged (D. Del.), 798
Switzerland, price-fixing alleged, 214

ERTACZO

Cream ad inaccuracies, FDA warns maker, 1051

ETHYOL

Cancer drugs patent dispute settled (D. Md.), 910

ETODOLOC

Arthritis drug contamination blamed for death, summary judgment granted for maker (E.D. Pa.), 708

EUROPEAN UNION (EU) *See also* specific countries

Antitrust exemption sought by drug firm, 1179
Cheaper drugs, drug makers suspected of blocking, 813
Generic drug shipments, action urged to prevent seizures, 240
Good Clinical Practices Initiative, FDA reaches agreement with EU agency, 919
Pfizer purchase of Wyeth under scrutiny, 657
R&D, EU signs off on public-private partnership projects, 628

EVISTA

Bone-building generic blocked (S.D. Ind.), 1130
Osteoporosis drug, automatic stay of generic approval upheld (Fed. Cir.), 225
TRO blocks generic (S.D. Ind.), 281; enjoined, 496

EVOCLIN

Acne foam maker seeks to block generic (D. Del.), 335

EXJADE

Iron chelating agent associated with renal failure, 1145

EXPERT WITNESSES

Accutane suit, expert excluded (M.D. Fla.), 1039
Diet drug suit, expert disqualified (E.D. Pa.), 825
Pain pump
—Deposition of expert ordered (D. Colo.), 914
—Shoulder joint damage, causation expert excluded (S.D. Fla.), 827
Seroquel, causation expert witness excluded (Del. Super. Ct.), 734
Viagra blame for nonarteritic anterior ischemic optic neuropathy, causation expert barred (D. Minn.), 1040
Zyprexa, causation expert who stretched the truth disqualified (E.D.N.Y.), 587

F**FALSE CLAIMS**

Aventis to settle false price report charges, 637
BNA audioconference, In Brief, 719; 781
Caremark qui tam suit, state court must resolve counterclaim immunity issue (5th Cir.), 856
Increased whistleblower suits possible, conference told, 779
Inflated prices, Mylan settles with state (D. Mass.), 40
Lipitor marketing qui tam action dismissed (E.D.N.Y.), 638

FALSE CLAIMS —Contd.**Medicaid**

- Fla. pharmacy accuses drug maker of inflating prices (S.D. Fla.), 62
- Ky. pharmacy (E.D. Ky.), In Brief, 1105
- Tex. amends false claims complaint against Risperdal makers (Tex. Dist. Ct.), 14
- Modified liability. *See* LEGISLATION, FEDERAL, S 386
- Off-label use
 - Antidepressants, feds intervene in suit (D. Mass.), 226
 - Lovenox qui tam suit may proceed (N.D. Ill.), 501
 - Natorecor whistleblower suits, feds intervene (N.D. Cal.), 226
- Off-label uses, Forest Labs settles (D. Mass.), 1166
- Procrit, qui tam suit against maker partially dismissed (1st Cir.), 968
- Public disclosure jurisdiction limited (U.S., rev grant), 729
- Retaliatory firing by Pfizer alleged, summary judgment granted for firm (S.D.N.Y.), 1136

FAMPRIDINE

MS drug cleared by FDA panel, 1235

FAMVIR

Herpes drug, infringement claim against generic maker may proceed (D.N.J.), 254; jury trial disallowed, 553

FANAPT

Schizophrenia drug approved for adults with warning, 539

FEDERAL TRADE COMMISSION (FTC)

Antitrust. *See generally* ANTITRUST

Leibowitz as FTC chair, more scrutiny predicted for drug industry, 261

Mergers and acquisitions. *See generally* MERGERS AND ACQUISITIONS

FEN-PHEN

Diet drug settlement, attorneys convicted of bilking plaintiffs (E.D. Ky.), 467

Fee award for attorneys affirmed (3rd Cir.), 1226

FENTANYL

Transdermal patch recall announced, 951

FENTORA

Pain drug, infringement claim over generic may proceed (D. Del.), 436

FLOMAX

Prostate drug, generic copy planned (N.D. Cal.), 1195

FLORIDA

"Manufacturer," definition revised, 778

Medicare, inhalation drug billings higher in Fla., 509

FLUCLOXACILLIN

Antibiotic associated with liver damage, 652

FLUTIFORM

Application, In Brief, 627; FDA may need more data, In Brief, 691

Asthma drug, additional clinical work urged, 1050

FOCALIN XR

ADHD drug, infringement claim dismissed (D.N.J.), 95

FOLOTYN

Lymphoma drug, FDA panel reports clinical benefit, 1049; approved, 1146

FOOD AND DRUG ADMINISTRATION (FDA)

ANDAs. *See* ABBREVIATED NEW DRUG APPLICATIONS (ANDAs)

Applications. *See* APPLICATIONS

Approvals. *See* APPROVALS

Budget for FY2010

—Funding bill. *See* LEGISLATION, FEDERAL, HR 2997, S 1406

Civil penalties, In Brief, 234

Commissioner

—Ex-commissioner joins Center for Health Transformation, 1116

—Nominee should be familiar with drug industry and have "impeccable qualifications," health coalition says, 16; consumer groups comment, 183; President to nominate Hamburg, 317; hearings planned, 537; Hamburg approved by Senate panel, 562; approved by Senate, 589; begins work, In Brief, 620; urged to work with CMS, 646

Conflicts of interest, panel member dismissed, Hinchey (D-NY) questions, 265

Enforcement

—Broader authority urged by MD group, 1147

—Compliance discussed at conference, 1078

—Increase predicted, 504

FY2010 budget

—Drug and device funding hiked, 560; deputy FDA chief testifies, 619

—Generic biotech drugs pathway included, 260

Grassley (R-Iowa) seeks clarification of employees right to discuss agency issues, 345

IT contracting criticized by HHS IG, 70

Labels and packaging. *See* LABELS AND

PACKAGING

Modernization projects, GAO urges comprehensive information technology program, 647

Safety. *See* SAFETY

Science, quality improvement discussed at conference, 654

Splitting FDA, Sebelius says speculation premature, 374

Transparency

—Pushed at Senate panel, 862; new commissioner supports, 946

—Task force announced, 645; industry and consumer groups comment, 740; more time for comments, In Brief, 1045; comments sought, 1174

Warnings. *See* WARNINGS

White House seeks regulatory review, 123

FORTAMET

Diabetes drug, generic ANDA challenged (D. Del.), 97

FORTICAL

Osteoporosis drug, generic blocked (S.D.N.Y.), 1028

FOSAMAX

Defense attorney's trip to Australia for deposition, plaintiffs must defray costs (S.D.N.Y.), 315; summary judgment denied, 1069

Degenerative jaw condition blamed on drug

(S.D.N.Y.), 1037; mistrial after jury deadlock, 1069

Osteoporosis drug product liability, amended claim to add second drug maker permitted (S.D.N.Y.), 118

Sales rep, suit against remanded to state court (S.D.N.Y.), 1170

FOSRENOL

Generic, brand-name maker seeks to block generic (S.D.N.Y.), 405

Kidney disease drug maker alleges patent infringement (S.D.N.Y.), 312

FRAUD AND ABUSE

Amgen accused of illegal marketing of Enbrel and Aransep (D. Mass.), 255

BNA plans conference, In Brief, 24

Discount drug card marketing claims settled (Pa. Commw. Ct.), 179

Foreign Corrupt Practices Act

—Compliance, Analysis & Perspective, 215

—More cases reported, 807

Fraud on agency claims, Analysis & Perspective, 1086

Generic drugs, Ala. Atty. Gen. seeks to dismiss suits against pharmacies for deceptive trade practices, 1204

Human growth hormone imports, Colo. pharmacy settles with DOJ (D. Colo.), 13

Joint venture to sell cancer drugs, \$3M award for negligent misrepresentation (5th Cir.), 799

Kickbacks. *See* ANTI-KICKBACK LAWS

Medicaid

—Ky. inflated AWP suit settled (Ky. Cir. Ct.), 311

—Mass. recoveries reported by Atty. Gen., 130

—Mo. settles with pharmacy, 975

—N.C. recoveries reported for 2008, 47

—Rebates not paid, 4 drug makers settle (D.N.H.), 1224

—Tex., immune system drug maker settles overcharge claims (Tex. Dist. Ct.), 969

—Wis., Pharmacia defrauded program through inflated prices (Wis. Cir. Ct.), 200; forfeitures sought, 556

Medicare Part D

—Average wholesale price

—Inflated prices, \$12.9M verdict affirmed (1st Cir.), 1125

—Overstating prices, dismissal vacated (1st Cir.), 1126

Misconduct in research

—Procedures to prevent revised by FDA, 947

Mishandling controlled substances, Rite Aid settles (E.D. Cal.), 97

Needy patients, drug maker assistance program cleared by HHS IG, 889

Off-label use. *See* OFF-LABEL USE

Oxycontin misbranding, Purdue Frederick ex-execs barred from federal programs, 119

Recoveries predicted by HHS IG, 686

Securities. *See* SECURITIES

Viread maker accused of misrepresenting sales (N.D. Cal.), 679; some shareholder claims may proceed, 1229

Walgreens accused of fraudulently switching dosage forms, dismissed (N.D. Ill.), 1030

Zyprexa, S.C. Atty. Gen. settles fraudulent marketing suit (S.C. Cir. Ct.), 1249

FTC *See* FEDERAL TRADE COMMISSION (FTC)

FTC *See* FEDERAL TRADE COMMISSION (FTC)

G**GABITRIL**

Epilepsy drug off-label marketing, dismissal denied (E.D. Pa.), 996

GARDASIL

Cervical cancer vaccine broader use, FDA seeks more data, 73; new indication approved, 1234

Male use urged by CDC panel, 1261

GEMZER

Cancer drug, method-of-use patent invalid (E.D. Mich.), 962

GENERIC DRUGS

Accutane discontinued due to generic competition, 780

Affordable generics. *See* LEGISLATION, FEDERAL, S 369

Ala. Atty. Gen. seeks to dismiss suits against pharmacies for deceptive trade practices, 1204

ANDAs. *See* ABBREVIATED NEW DRUG APPLICATIONS (ANDAs)

Anti-rejection drug copy, FDA may approve (D.D.C.), 967

Applications

—Backlog, FDA to address, 1077

—Copaxone, In Brief, 1085

—Duac, In Brief, 1116

Approvals

—Accretic, In Brief, 298

—Alkeran, In Brief, 691

—Altace, In Brief, 298

GENERIC DRUGS—Contd.

Approvals—Contd.

—Antizol, In Brief, 1150
—Atripla, In Brief, 977
—Biotech drugs. *See* LEGISLATION, FEDERAL, HR 1427
—Casodex, In Brief, 810
—Catapres TTS, In Brief, 977
—CellCept, In Brief, 571
—Cytomel, In Brief, 871
—Depakote ER, In Brief, 953
—Depakote, In Brief, 164
—Eloxatin, In Brief, 952; approval suspended, 963; reinstated, 1001
—Flomax, In Brief, 1178
—Haldol, In Brief, 871
—Idamycin, In Brief, 952
—Imitrex
— —Mylan, In Brief, 952
— —Raxbaxy, In Brief, 952
—Kaletra, In Brief, 324
—Keppra, In Brief, 104
—Klaron, In Brief, 386
—Lamictal, In Brief, 133
—Lithium carbonate, In Brief, 192
—Mircette, In Brief, 50; 51
—Plan B, generic by Duramed approved, 741; Watson generic approved, 1055
—Precose, In Brief, 627
—Prilosec, In Brief, 134
—Restoril, In Brief, 720
—Roxicodone, In Brief, 451
—Sinemet, In Brief, 1149
—Singulair, In Brief, 656
—Starlix, In Brief, 1085
—Sun Pharma, In Brief, 49
—Tegretol-XR, In Brief, 418
—Toprol XL, In Brief, 927
—Zerit, In Brief, 51
—Zithromax, In Brief, 385; 782
—Zosyn, generic approval challenged (D.D.C.), 1099
Aurobindo, In Brief, 272
Authorized generics
—Ban on sales by brand-name maker, 265
—Information submission, FDA withdraws rule, 181; final rule issued, 886
—Listing from FDA urged by senators, 206
—Marketing ban. *See* LEGISLATION, FEDERAL, HR 380
BCBS, community-based programs expanding use, 450
BenzaClin, In Brief, 1056
Biogenerics. *See* BIOGENERICS
Biologics, In Brief, 782
Biosimilars. *See* LEGISLATION, FEDERAL, HR 1548
Biotech drugs. *See* LEGISLATION, FEDERAL, S 726
Budget for FDA includes pathway for generic biotech drugs, 260
Caraco drugs seized by FDA, 781
Delaying release. *See* LEGISLATION, FEDERAL, HR 1706
Delays. *See* LEGISLATION, FEDERAL, S 1778
Digoxin, In Brief, 418
Doryx. *See* DORYX
Duac maker claims infringement (D. Del.), 640
Effexor. *See* EFFEXOR
Efudez, investment firm accused of giving trade secrets to competitor (D. Del.), 523
Elevance, In Brief, 926
Enablex, In Brief, 515
EU, action urged to prevent seizures of drug shipments, 240
Evista. *See* EVISTA
Evoclin, In Brief, 324
“Facts and myths,” at FDA website, In Brief, 806
Flomax copy planned (N.D. Cal.), 1195
Flonase, In Brief, 325
Fludara, In Brief, 926

Fortical generic blocked (S.D.N.Y.), 1028
Imitrex, In Brief, 237
Immunosuppressants, FDA denies petition to additional measures to protect transplant recipients, 951
Japan, manufacturing allowed before patent expiration, 487
Levitra generic challenged (D. Del.), 798
Lexapro, declaratory judgment against generic maker dismissed (U.S., rev den), 227
Medicaid. *See* MEDICAID
Medicare. *See* MEDICARE DRUG COVERAGE
Metoclopramide, brand name maker liable for neurological condition blamed on generic (Cal.), 117
Miacalcin, In Brief, 691
Minn. pricing law, union funds sue pharmacy chains (D. Minn.), 1029
Naropin, generic blocked (D.N.J.), 907; appealed, 1035
N.Y., generic use down upstate, 209
Patents
—Actonel. *See* ACTONEL
—Adderall XR, generic maker to get license (D. Colo.), 1195
—Allegra. *See* ALLEGRA
—Alphagan, generic infringes patent (D. Del.), 1248
—Aricept infringement alleged, inequitable conduct defense permitted (D.N.J.), 796
—Avinza, infringement alleged over ANDA (D.N.J.), 1071
—Carbatrol generic challenge settled (S.D.N.Y.), 1100
—Clarinex, generic permitted (D.N.J.), 943
—Clarinex suit settled (D.N.J.), 437
—Codexis biocatalyst, In Brief, 49
—Combigan generic challenged (E.D. Tex.), 438
—Concerta, generic no infringement (D. Del.), 364
—Contan and Stalevo, infringement claims settled (D. Del.), 526
—Eloxatin. *See* ELOXATIN
—Emend, generic plans challenged (D.N.J.), 284
—Ethyol dispute settled (D. Md.), 910
—Evoclin maker seeks to block generic (D. Del.), 335
—Exclusivity. *See* LEGISLATION, FEDERAL, S 1315
—Femcon Fe settlement (D.N.J.), In Brief, 15
—Fentora, infringement claim over generic may proceed (D. Del.), 436
—Ferrelec license, In Brief, 896
—Fosrenol maker seeks to block generic (S.D.N.Y.), 405
—Loestrin 24, generic sales opposed (D. Del.), 1068
—Mucinex D generic ANDA challenged by patent holder, 690
—Namenda generic challenge, some firms dismissed (D. Del.), 1100
—Omnicef, generic created by different process no infringement (Fed. Cir.), 605
—Opana ER, infringement suit over generic dismissed (D.N.J.), 230
—Ortho Tri-Cyclen maker challenges generic (D.N.J.), 733; generic maker halts shipments, 836; settled, 879
—Patanol, infringement alleged (S.D. Ind.), 202
—Pfizer Indian licenses announced, 624
—Prandin patent validity, summary judgment denied (E.D. Mich.), 733
—Pulmicort maker seeks to block generic (D.N.J.), 436; blocked, 461; preliminary injunction, 610
—Seroquel generic challenged (D.N.J.), 203
—Strattera drug direct infringement claim dismissed (D.N.J.), 609
—Valcyte patent valid, generic does not infringe (D.N.J.), 1189; appealed, 1251
—Vanos infringement dispute settled (W.D. Mich.), 463
—Vfend, In Brief, 1238
Paxil, supply and license contract dispute, \$70M awarded for breach (N.D. Ill.), 201
Prices lower when “authorized generics” marketed, FTC reports, 737

Prilosec, generic did not infringe (S.D.N.Y.), 309
Protonix, generic advertising challenged (E.D. Mich.), 554
Reglan blamed for movement disorder, failure-to-warn claim against generic maker not preempted (D. Vt.), 6; review denied, 465
Reverse payment deals targeted by FTC, 372
Risk Evaluation and Mitigation Studies, FDA urged to prevent firms from blocking generics, 780
Risperdal. *See* RISPERDAL
Rocaltrol, In Brief, 1054
Singulair generic blocked (D.N.J.), 961
Solodyn. *See* SOLODYN
Tindamax, In Brief, 163
Topamax. *See* TOPAMAX
Tricor, consumer suit over generic delay, settlement approved (D. Del.), 500
Vancocin, FDA panel approves testing guidelines, 922
Wellbutrin, generic makers accused of making inferior product (Cal. Super. Ct.), 706
Xeloda, generic challenged (D.N.J.), 438
Xopenex, dispute over generic settled (D. Del.), 286
Xyzal. *See* XYZAL
Zofran, In Brief, 926

GENETICS AND BIOTECHNOLOGY

Biogenerics, AARP supports, 624
Biologics. *See* BIOLOGICS
Biosimilars. *See* LEGISLATION, FEDERAL, HR 1548
Data exclusivity, biotech industry seeks 14 years, 131
Generic drugs. *See* LEGISLATION, FEDERAL, S 726
Health reform, biosimilars pathways sought by governors, 1142
Long exclusivity period pushed at conference, 622
Personalized medicine. *See* PERSONALIZED MEDICINE
Securities fraud class actions “differed dramatically” in 2008, survey finds, 484
Unpatentable law of nature, gene expression at issue (Fed. Cir.), 172; rehearing granted, 988

GEODON

Adolescents, FDA panel backs use for mental illnesses, 715

GEORGIA

Product liability, governor proposes protection for drug and device makers, 209

GLEEVEC

Gastrointestinal cancer drug approved, 23

GRANTS

Schizophrenia drug funding, In Brief, 133

H

H1N1 VIRUS

Fraudulent H1N1/swine flu cures, FDA and FTC warn public, 537
Funding for H1N1/swine flu sought by White House, 534
Peramivir, FDA clears for emergency use, 1261

HEALTH AND HUMAN SERVICES DEPARTMENT (HHS)

Comparative effectiveness panel members named, 343
Daschle pledges to improve operation of FDA and other agencies, 69; withdraws name, 156; Sebelius nominated, 263; Senate action delayed, 407; finance panel approves, 470; Senate approves, 503
FDA. *See* FOOD AND DRUG ADMINISTRATION (FDA)
FY2010 budget includes Medicaid cuts, 560; more FDA drug and device funding, 560
Stimulus funding office launched, 291

HEALTH CARE REFORM, FEDERAL

Baucus (D-Mont) proposal includes rebates and drug maker fees, 1042; released, 1074; bill, *see* LEGISLATION, FEDERAL, S 1796

Biosimilars pathways sought by governors, 1142; Senators seek, 1201

Boehner (R-Ohio) opposes White House deal with industry, 974

Comparative effectiveness. *See* COMPARATIVE EFFECTIVENESS

Daschle withdrawal may slow down reform efforts, 156

Democrats bill analyzed, 777

Device and drug makers urge coverage expansion, 776

Finance panel clears Senate bill, 1199

GOP senators drafting proposal, 711

Hatch (R-Utah) expects bipartisan bill to pass in 2009, 472

HELP panel releases draft Senate bill, 683; markup, 739; biosimilars pathway sought, 1201

Marketing, drug firms may need to overhaul strategies, 717

PBM transparency included in Senate bill, 1138

Personalized medicine pushed by Merck CEO, 566

Pharmacists offer reform principles, 210

Public option. *See* LEGISLATION, FEDERAL, HR 3200

Rationing. *See* LEGISLATION, FEDERAL, S 1259

Stakeholders pledge savings, 652

HEPARIN

Adverse reaction, suit remanded to state court (S.D. Ala.), 255

Approvals, In Brief, 1055

Blood thinner not tied to adverse events in 3 patients, maker says, 594

Chinese firms get warning from FDA on contamination, 476

Potency cut by manufacturing change, 1174

HIBERIX

Flu vaccine gets accelerated approval, 1002

HORMONE REPLACEMENT THERAPY (HRT)

Breast cancer blamed on HRT

—Non-resident plaintiff, Minn. limitations period applies (Minn.), 1036

—Summary judgment for maker (Minn. Ct. App.), 884

Failure-to-warn claim against maker not preempted (Tex. App.), 464

Ghostwriting by maker, documents unsealed (E.D. Ark.), 915

Jurisdiction lacking over ad firms with insufficient W.Va. contacts (E.D. Ark.), 367

HRT *See* HORMONE REPLACEMENT THERAPY (HRT)

HUMAN SUBJECT PROTECTION

IRBs. *See* INSTITUTIONAL REVIEW BOARDS (IRBs)

Pfizer study subject protection program accredited, 417

HUMIRA

Arthritis drug maker alleges patent infringement (D. Mass.), 526

Patent infringement alleged (E.D. Tex.), 41; summary judgment for plaintiff denied, 585; summary judgment for defendant denied, 671; \$1.67M awarded, 767

Psoriasis and arthritis drug ad broadens approved indication and minimizes risks, FDA says, 21

HYTRIN

Hypertension and prostate drug monopoly claim remanded (9th Cir.), 91

I

IBUPROFEN

Injectable dosage approved by FDA, 717

ILLINOIS

Medicaid, inflated prices, drug maker settles, 821

Plan B, pharmacists challenge to dispensing requirement may proceed (Ill.), 7

INDIA

Safety, FDA opens offices in India, 99

Tarcera patent infringement suit dismissed, 543

INFLUENZA

CVS Caremark, In Brief, 1055

H1N1. *See* H1N1 VIRUS

Hiberix vaccine gets accelerated approval, 1002

INFORMATION NETWORKS AND TECHNOLOGY

E-health. *See* E-HEALTH

Electronic prescriptions. *See* E-PRESCRIPTIONS

Internet. *See* INTERNET

INSTITUTIONAL REVIEW BOARDS (IRBs)

Coast IRB enters voluntary agreement with FDA limiting activities, 442; shutdown, 514

INTELENCE

HIV drug labels revised due to skin reactions, 1051

INTERMEZZO

Insomnia drug, FDA wants more data, 1263

INTERNATIONAL DEVELOPMENTS *See also*

specific countries

Imported drugs

—Access bill. *See* LEGISLATION, FEDERAL, S 525

—Billings, Mont., importer held in contempt (Mont. Dist. Ct.), 154

—Canadian imports. *See* LEGISLATION, FEDERAL, HR 2892

—Chemical makers raise safety issues, 1263

—Dorgan (D-ND) and Snowe (R-Me) expect bipartisan bill to pass, 68

—Good importer practices, agencies issue guidance, 66

—Regulatory outlook 2009, 80

—Safe importation bill offered in Senate, 264

Market growth for drugs estimated for 2009, 513

UN Oil for Food Program, Danish firm settles kickback charges (D.D.C.), 558

WTO drug access pact defended, 839

INTERNET

Clinical trials, website seeks to improve participation, 977

E-health. *See* E-HEALTH

Electronic prescriptions. *See* E-PRESCRIPTIONS

Internet pharmacies. *See* INTERNET PHARMACIES

Risk information lacking from many Internet ads, 413

State developments

—Pa. price database launched, 293

—Wyo. drug database access bill signed, 321

Ultram ER web video called misleading by FDA, 623

INTERNET PHARMACIES

N.J. Assembly approves regulation, 321

Owner pleads guilty (E.D. Mo.), In Brief, 972

IOWA

E-prescriptions promoted for MDs, 1236

Medicaid, HHS rejection of drug plan amendment upheld (8th Cir.), 890

Physician gifts, Senate approves ban, 349

IPLEX

ALS patients to have access, 288

IRBs *See* INSTITUTIONAL REVIEW BOARDS (IRBs)

ISENTRESS

AIDS drug price cut sought, 892

J

JAPAN

Generic manufacturing allowed before patent expiration, 487

JURISDICTION

AndroGel, class actions seek to recoup charges paid due to collusion between brand name and generic firms, transferred to Ga. federal court (C.D. Cal.), 435

Blood factor concentrates, Taiwanese hemophiliacs suits may proceed in Cal. (N.D. Ill.), 96

Elidel suits remanded (D.N.J.), 734

Heparin adverse reaction, suit remanded to state court (S.D. Ala.), 255

Lipitor infringement suit stayed over jurisdiction issues (N.D. Ill.), 703

Reglan liability suit properly removed to federal court (E.D. Pa.), 529

Risperdal, jurisdiction lacking to hear patent counterclaims (U.S., rev den), 340

K

KALETRA

AIDS drug, price cut in Mexico, 387

Promotional DVD overstated efficacy and minimizes risks, FDA says, 862

KENTUCKY

Medicaid, \$16M awarded for price inflation (Ky. Cir. Ct.), 768

Medicaid, inflated AWP suit settled (Ky. Cir. Ct.), 311

KETEK

Antibiotic, concealment of hazards alleged, depositions blocked (E.D.N.Y.), 557

KICKBACKS *See* ANTI-KICKBACK LAWS

L

LABELS AND PACKAGING *See also* SAFETY; WARNINGS

Acetadote, In Brief, 26

Antibacterials, FDA issues guidance, 802

Asthma drug makers asked by FDA to add precaution on adverse events, 718

Botulism toxin drugs get boxed warnings, 919

Comparative effectiveness, FDA urged to include data on label, 1148

Epilepsy drug suicide risk, FDA approves warning labels, 532

Erbix label revision approved by FDA, 870

Evolence, In Brief, 691

Industry guidance issued by FDA, 1231

Intelligence labels revised due to skin reactions, 1051

Kidney transplant drug, FDA requires updated labels, 835

Libel, packaging product criticized in journal, suit dismissed (S.D. Ind.), 405

Metoclopramide must add box warning on risks of long-term or high-dose use, 269

Orencia, In Brief, 1056

Pegintron, In Brief, 325

Preemption of state laws, White House seeks review of rules, 618

Promethazine hydrochloride injection gets boxed warning, 1077; Analysis & Perspective, 1151

Propoxyphene, FDA orders boxed warning, 803

Rebetol, In Brief, 325

Smoking cessation products and serious mental health events, FDA orders boxed warning, 803

LABELS AND PACKAGING —Contd.

Testosterone gel to get box warning, 565
Toll-free number on medication guides, FDA issues guidance, 351
Vyvanse, In Brief, 656

LAMICTAL

Epilepsy drug sold at discount, no settlement breach (D.N.J.), 763

LANTUS

Diabetes drug, FDA examines cancer risk, 809

LEAQUIN

Antibiotic blamed for tendon rupture (D. Minn.), 1170

LEGISLATION, FEDERAL

Ed. Note: This heading covers bills with assigned numbers. For information on measures not yet assigned numbers, see specific subject headings.

HR

—**1**, American Recovery and Reinvestment Act, includes comparative effectiveness research, 126; House approves, 180; signed, 205; industry cautiously optimistic, 241
—**380**, Authorized generic drugs marketing ban, Emerson (R-Mo), 99
—**684**, Medicare Prescription Drug Savings and Choice Act, Berry (D-Ark), would create drug plan under traditional program, 125
—**759**, Food and Drug Administration Globalization Act, would require international parity in inspections, expand FDA powers, 128
—**1260**, Patent Reform Act, Conyers (D-Mich), would create first-to-file system, 262; House urged to conform bill to S 515, 535
—**1427**, Promoting Innovation and Access to Life-Saving Medicine Act, Waxman (D-Cal), Pallone (D-NJ), Deal (R-Ga), Emerson (R-Mo), would allow FDA to approve generic versions of expensive biotech drugs, 287; pressure high to pass, 472
—**1450**, Counterfeit Drug Prevention Act, Rogers (R-Mich), would create criminal penalties, 319
—**1548**, Pathway for Biosimilars Act, Eshoo (D-Cal), Inslee (D-Wash), Barton (R-Tex), would create regulatory path at FDA, 318; Johnson & Johnson supports, 407; New Democrat Coalition supports, 508; Eshoo wants quick action, 590; Eshoo to offer bill as amendment, 832; hearing addresses competition, prices, innovation, 832; industry groups comment, 859
—**1706**, Protecting Consumer Access to Generic Drugs, would bar brand-name firms from pay for delays, FTC chief supports, 371; House panel approves, 642; hearing held, 642
—**1859**, Independent Drug Education and Outreach Act, Waxman (D-Cal), Pallone (D-NJ), would create academic detailing program to provide MDs with unbiased drug information, S 767 is companion, 374
—**2892**, Homeland Security funding, amendment allows imports from Canada, 864
—**2997**, Agriculture Appropriation Act, House approves FDA funding hike, 834; FDA funding approved by Senate, In Brief, S 1406 is companion, 920; conference report approved, 1202; signed, 1257
—**3200**, America's Affordable Health Care Choices Act, Democratic bill to create public option, revise Medicaid and Medicare drug coverage, 830; will not reach floor before recess, 886; Stark (D-Cal) defends kidney drug provision, 889; House energy and commerce panel approves, 917; PBM transparency sought, 999; CBO reports, 1045; BIO supports, 1048; Waxman (D-Cal) seeks generic biologics pathway, 1108
—**3663**, Medicare pharmacist accreditation requirement delayed, Senate approves, 1173

SConRes

—**13**, FY2010 budget resolution, Kyl (R-Ariz) amendment on research-based delays rejected, 409

S

—**1**, American Recovery and Reinvestment Act, includes comparative effectiveness research, 126; Senate approves, 180
—**301**, Physician Payment Sunshine Act, Kohl (D-Wis) and Grassley (R-Iowa), would require firms to report payments and gifts to MDs, 127
—**369**, Preserve Access to Affordable Generics Act, Kohl (D-Wis) and Grassley (R-Iowa), would ban makers from paying firms to keep generics off market, 155; FTC says ban would produce savings, 738; Senate panel likely to modify, 1076; brand name-generic settlements presumed illegal, 1139; Senate panel approves, 1230
—**386**, Fraud Enforcement and Recovery Act (FERA) of 2009, expands False Claims Act liability, signed, 619
—**501**, Fair Prescription Competition Act, Rockefeller (D-WVa), would bar sale of authorized generics by brand-name maker, 265
—**515**, Patent Reform Act, Leahy (D-Vt) and Hatch (R-Utah), would create first-to-file system, 262; Senate action delayed, 344; compromise possible soon, 375; compromise approved, 408; HR 1260 is counterpart, 535; panel report, 563
—**525**, Pharmaceutical Market Access and Drug Safety Act, importation amendment rejected, 773
—**610**, Patent Reform Act, Kyl (R-Ariz), would rewrite provisions concerning conditions for patentability, 344
—**726**, Promoting Innovation and Access to Life-Saving Medicine Act, Brown (D-Ohio), Schumer (D-NY), Collins (R-Maine), Martinez (R-Fla), Stabenow (D-Mich), Vitter (R-La), would allow FDA to approve generic version of biotech drugs, 372
—**767**, Independent Drug Education and Outreach Act, Kohl (D-Wis), Kennedy (D-Mass), Durbin (D-Ill), would create academic detailing program to provide MDs with unbiased drug information, HR 1859 is companion, 374
—**882**, Drug and Device Accountability Act, Kennedy (D-Mass) and Grassley (R-Iowa), would increase FDA resources to inspect drugs, 507
—**1110**, Medicare Payment Advisory Commission (MedPAC) Reform Act, Rockefeller (D-WVa), would create executive branch agency, 620
—**1232**, Pharmaceutical Market Access and Drug Safety Act, Dorgan (D-ND), Snowe (R-Me), McCain (R-Ariz), would allow importation of lower-cost drug, 1107
—**1259**, Preserving Access to Targeted, Individualized, and Effective New Treatments, Kyl (R-Ariz) and McConnell (R-Ky), seeks to prevent rationing, 711
—**1315**, Drug Price Competition Act, Nelson (D-Fla), would expand availability of 180-day exclusivity for generic firms that challenge patents, 773
—**1406**, FDA funding approved by Senate, In Brief, HR 2297 is companion, 920
—**1778**, Access to Affordable Medicines Act, Shaheen (D-NH) and Vitter (R-La), would block delays by brand name drug makers, 1232
—**1796**, America's Healthy Future Act, Baucus (D-Mont), health reform bill include generic prescribing, 1143; markup, 1172
—**1859**, Independent Drug Education and Outreach Act, Kohl (D-Wis), Kennedy (D-Mass), Durbin (D-Ill), would create academic detailing program to provide MDs with unbiased drug information, 374

LETAIRIS

Hypertension drug, FDA alleges misleading comments by maker, 295

LEVAQUIN

Antibiotic patent term extension approved (D.N.J.), 607
Discovery costs denied in patent dispute (Fed. Cir.), 702

LEVITRA

Erectile dysfunction drug, generic challenged (D. Del.), 798

LEXAPRO

Antidepressant approved for adolescents, 350
Competing patents, two claims invalidated by prior art (S.D.N.Y.), 673
Declaratory judgment against generic maker dismissed (U.S., rev den), 227
Destruction of electronic records alleged (E.D. Mich.), 462; settlement reached, 836

LIPITOR

Cholesterol drug infringement suit stayed over jurisdiction issues (N.D. Ill.), 703
Deceptive promotion claims dismissed (S.D.N.Y.), 1161
Marketing qui tam action dismissed (E.D.N.Y.), 638
Technical fix on patent, In Brief, 50

LIRAGLUTIDE

Diabetes drug cancer risk disputed, 414

LIVALO

Schizoaffective disorder drug approved, 923

LOESTRIN 24

Contraceptive, generic sales opposed (D. Del.), 1068

LOTREL

Hypertension drug, low-dose ANDA challenged as infringement (D.N.J.), 13; dismissed, 201
Infringement claim dismissed without prejudice (D.N.J.), 1068

LOVENOX

Anticoagulant off-label use, qui tam suit may proceed (N.D. Ill.), 501
Blood clot drug patent not enforceable (U.S., rev sought), 171; (rev den), 495

LUMIZYME

Pompe disease treatment, FDA seeks more information, 270

M

MARKETING *See also* ADVERTISING; CONFLICTS OF INTEREST

Academic detailing program. *See* LEGISLATION, FEDERAL, HR 1859, S 767
Aplenzin, In Brief, 24
Authorized generics marketing ban. *See* LEGISLATION, FEDERAL, HR 380
Bexra illegal marketing, Pfizer fined \$1.2B, 1047
Biogenerics, In Brief, 1208
Caldolor, In Brief, 1053
Cefazolin, In Brief, 191
Centany, In Brief, 516
Cerezyme, In Brief, 1116
Cholesterol drug makers accused of deceptive promotion (E.D. Pa.), 678
Colchicine not enjoined (C.D. Cal.), 1249
Convenience drug kits, In Brief, 872
Creon, In Brief, 811
Cyanokit, In Brief, 1265
Discount drug card marketing claims settled (Pa. Commw. Ct.), 179
Edluar, In Brief, 1053
Eisai and Pfizer, In Brief, 1150
Embeda videos, FDA says risks omitted or minimized, 1235
Emsam, In Brief, 656
Epiduo Gel, In Brief, 50
Exactacain, In Brief, 272
Fabrazyme, In Brief, 1116
Firmagon, In Brief, 926
Gelnique launch, In Brief, 627
Global outlook for industry reported, 1207

MARKETING —Contd.

Grassley (R-Iowa) queries medical journals on ghostwriting policies, 805
Health care reform, drug firms may need to overhaul strategies, 717
Hydrelle, In Brief, 811
J&J fined over misleading materials for MDs (W.Va. Cir. Ct.), 283
Kaletra promotional DVD overstated efficacy and minimizes risks, FDA says, 862
Kapindex, In Brief, 238
Keppra XR, In Brief, 451
Letairis, FDA alleges misleading comments by maker, 295
Lipitor deceptive promotion claims dismissed (S.D.N.Y.), 1161
MDV3100, In Brief, 1265
Medical education funding, GSK limits, 1113
Megace maker target of DOJ, 381
Mircera sales ban upheld (Fed. Cir.), 1097
Moxatag, In Brief, 49
Naprelan, In Brief, 78
NTC-801, In Brief, 298
Off-label promotion and use. *See* OFF-LABEL USE
Opioids, FDA warns firms marketing unapproved drugs, 1206
Overtime for salespersons
—Bayer, guidance sought from Cal. court (9th Cir.), 555
—Novartis, overtime denied (S.D.N.Y.), 121
Oxycodone, In Brief, 486
Prices. *See* PRICING
Rapaflo, In Brief, 418
Risperdal, In Brief, 656
Savella, In Brief, 298; 486
Seroquel false promotion suit remanded to state court (D.N.M.), 852
State developments
—Mass., licensing of drug and device agents, Senate bill amended, 688; dropped from budget, 743
—Vermont
—Gift ban for drug firms, expansion approved, 592; signed, 688
—Pending by drug firms reported, 474
Sumavel DosePro, In Brief, 927
Surfaxin, In Brief, 1085
Timoptic, In Brief, 237
Toviaz, In Brief, 655
Uloric, In Brief, 325
Unapproved drugs. *See* SAFETY
Uramaxin, In Brief, 516
Uroxatral, FDA calls promotional materials misleading, 1262
Valstar, In Brief, 1054
Vaprisol, In Brief, 384
Vyvanse, In Brief, 385
Zometa not withdrawn for safety or effectiveness reasons, FDA says, 448

MASSACHUSETTS

Conflicts of interest
—Fees for covered firms due Jul. 1, 648
—Gifts to MDs, limits criticized, 71; conferences moved from Boston, 129; creates controversy, 158; final rules adopted, 292
—Hospital network to limit interaction with industry, 441
E-prescriptions, Mass. leads states for third year, 746
False claims, inflated prices, Mylan settles with state (D. Mass.), 40
Licensing of drug and device agents, Senate bill amended, 688; dropped from budget, 743
Medicaid
—Pricing suit against drug maker, nationwide settlement does not bar suit (D. Mass.), 311
—Recoveries reported by Atty. Gen., 130

MAXIPIME

Antibiotic, no higher mortality risk reported by FDA, 716

MEDICAID

Alabama
—E-prescribing system announced in Ala., 648
—Pricing suits
—5 firms settle with state (Ala. Cir. Ct.), 40; jury awards \$78.4M (Ala. Cir. Ct.), 227; more firms settle (Ala. Cir. Ct.), 610
Cal., Medi-Cal cuts challenged by pharmacists (C.D. Cal.), 151; cuts enjoined, 256; hospital and pharmacy reimbursement cuts blocked (9th Cir.), 404
Comments added to administrative record, HHS must produce (D.D.C.), 765
Controlled substances, improper payments reported, 1144
Del., Omnicare to settle overcharging claims, 638
Drug reimbursement rule delayed (D.D.C.), 228
Fraud. *See* FRAUD AND ABUSE
FY2010 budget includes cuts, 560; pharmacy groups oppose, 1082
Generic drugs
—Payment revisions urged, 538
—Reimbursement gap with Medicare reported by HHS IG finds, 268
Iowa, HHS rejection of drug plan amendment upheld (8th Cir.), 890
Ky., \$16M awarded for price inflation (Ky. Cir. Ct.), 768
Mass., pricing suit against drug maker, nationwide settlement does not bar (D. Mass.), 311
Pharmacy groups sue over reimbursements (C.D. Cal., N.D.N.Y., W.D. Wash.), 1165
PhRMA and Families USA unveil expansion campaign, 485
Poor Medicare enrollees move to Medicaid could cut costs, 925
Pricing
—Average manufacturer price, reimbursement cuts opposed by pharmacy stakeholders, 1111
—Ill. settles with drug maker over inflated prices, 821; recovery announced, 882
Protonix overcharges alleged (D. Mass.), 582
Rebate hike considered in Senate, 589
Regulatory outlook 2009, 80
Reporting mandate, safety-net hospitals settle with CMS, 1199
TennCare dual eligibles reimbursed at 100 percent of Medicare charge, bill signed, 865
Utah recovers overcharges from Dey, 1112
Wash. pharmacy reimbursement cuts blocked (W.D. Wash.), 403; agency to reexamine cuts, 592; agency to cut reimbursements, 621

MEDICARE ADVANTAGE (MA)

Policy and technical changes proposed by CMS, 1202

MEDICARE DRUG COVERAGE

Ed. Note: Entries at this heading refer to Medicare Part D unless otherwise indicated.
Adjusting reimbursements, HHS IG finds potential savings, 508
Advt coding upheld (D.D.C.), 971
Compendia, conflicts of interest seen as inherent, 625
E-prescriptions
—Implementation reported, 1233
—Technical problems limit ability of sponsors to meet standards, HHS IG reports, 1233
Executive agency status for MedPAC. *See* LEGISLATION, FEDERAL, S 1110
Fee schedule for MDs, proposal would remove office drugs from formula, 804
Formularies, lower total reported for 2010, 1203
Gap in coverage
—Discounts for some enrollees promised by drug makers, 744
—Sickest beneficiaries, Democrats proposal may harm, 810
Generic drugs
—Biotech drugs pushed, savings predicted, 320

—Reimbursement gap with Medicaid, HHS IG reports, 268
Industry ties to MDs, MedPAC reports, 266
Inhalation drugs, utilization shifts, 1044
Negotiated prices
—Cost sharing rule issued by CMS, 42
—Opposed by ex-CMS chief, 207
Off-label use
—Conditions for coverage more complex for drugs than devices, 382
—Ovarian cancer treatment, contractor to cover, 471
—State Attys. Gen. support CMS proposal to block insurers' requirement, 345
Oversight a challenge for HHS, 43
Performance of program examined, 894
Pharmacist accreditation. *See* LEGISLATION, FEDERAL, HR 3663
Pharmacogenomic testing of anticoagulants covered only for clinical trials, CMS proposes, 531
Policy and technical changes proposed by CMS, 1202
Poor enrollees move to Medicaid could cut costs, 925
Premium hike announced, 973
Prices. *See* PRICING
Protected drug classes. CMS issues rule, 100; managed care group opposes expansion, 346
Roche bids for Genentech, 162
Traditional program. *See* LEGISLATION, FEDERAL, HR 684
Trends
—Accessibility to drugs increased by program, 76
—Biologics use limited, 412
—Inhalation drug billings higher in Fla., 509
—Outpatient drug spending reported, 412
Utilization management data, CMS urges plan sponsors to outline of websites, 376
Warfarin, Medicare to cover clinical trial, 948

MEGACE

Eating disorder drug marketing, maker target of DOJ, 381

MENTAL HEALTH

Grassley (R-Iowa) seeks information on Natl. Alliance for Mental Illness, 1257

MERGERS AND ACQUISITIONS

Abbott and Solvay drug business, In Brief, 1149
Alprostadil, In Brief, 163
Astellas wants CV Therapeutics, In Brief, 134; bid rejected, 238; offer dropped, In Brief, 324
Biogen makes bid for Facet Biotech, 1083
Bristol-Myers and Medarex, In Brief, 896
Caraco completes asset from Forest Labs, 1177
Cephalon
—Arana, In Brief, 272
—BioAssets, In Brief, 1265
—Ception, In Brief, 105
CVS Caremark merger, FTC probe sought, 565; pharmacists group alleges monopoly, 565
Degarelix, In Brief, 271
Desonate and NeoBenz Micro, In Brief, 1054
Endo and Indevus, In Brief, 50; 352
Express Scripts to buy WellPoint PBMs, 448; community pharmacists oppose, 512
Gilead to buy CV Therapeutics, 323
GSK
—Genelabs, In Brief, 49
—Stiefel, In Brief, 486
Helsinn and Sapphire, In Brief, 133
Hisamitsu and Noven, In Brief, 837; complete, In Brief, 1055
J&J
—Cougar purchase planned, 624; FTC clears, 748; completed, 838
—Investing in Elan, 809; Elan collaboration planned with Biogen, terms of Johnson & Johnson deal modified, 1082
—Omrix purchase, In Brief, 51
LFA-1 inhibitor, In Brief, 298
Licensing. *See* PATENTS

MERGERS AND ACQUISITIONS—Contd.

Lundbeck and Ovation, In Brief, 191
Merck to buy Schering-Plough, 295; effect on innovation, FTC urged to examine, 449; shareholders approve, In Brief, 952
Novartis seeks generic injectables business, In Brief, 627; purchase of EBEWE cleared, 1148
Onyx to buy Proteolix, In Brief, 1208
Pfizer
—Insulin factory, In Brief, 297
—Wyeth purchase, 131; FTC wants more data, 418; effect on innovation, FTC urged to examine, 449; under EU scrutiny, 657; EU requires divestitures, 868; merger challenged (N.D. Cal.), 991; FTC clears, 1193; pharmacists challenge dismissed (N.D. Cal.), 1223
Pharmexa and Affitech, 271
Piramal and Minrad, In Brief, 24
PPD buys vaccine testing lab, 48
Roche
—Genentech purchase planned, 296; tender offer, In Brief, 385
—Memory, In Brief, 51
Sanofi and Fovea, In Brief, 1178
Sanofi purchase of Zentivz, EU agencies require spinoffs, 214
Sepracor, In Brief, 1054
Takeda to buy IDM Pharma, In Brief, 595
Teva, Barr purchase cleared by FTC, 23
Tysabri maker breached collaboration pact (S.D.N.Y.), 1029
Warner Chilcott and P&G drug business, In Brief, 1004
Watson and Arrow, In Brief, 719; FTC seeks information, 953
Wyeth
—Pfizer merger agreement reached, 942
—Thiakis purchase, In Brief, 25
Zevalin, In Brief, 238

METOCLOPRAMIDE

Brand name maker liable for neurological condition blamed on generic (Cal.), 117
Failure to warn claims
—Fla., preempted (W.D. Fla.), 231
—Ky., preempted (W.D. Ky.), 231
Gastrointestinal drug makers must add box warning on risks of long-term or high-dose use, 269
Heartburn drug blamed for neurological injuries (MDL), 708

MEXICO

Kaletra price cut, 387

MICHIGAN

Immunity for drug firms, House approves repeal, 378

MINNESOTA

Conflicts of interest
—Forest Lab payment to MDs reported, 1080
—Gifts to MDs, bill to ban withdrawn, 378
Generic pricing law, union funds sue pharmacy chains (D. Minn.), 1029
Psychiatric clinical trial limits, bill signed, 593

MINOCIN

Anti-bacterial drug, failure-to-warn claim not preempted (N.D. Ill.), 364

MIRAPEX

Anti-competitive tactics allegedly used to block generic (W.D. Pa.), 1035
Restless leg drug blamed for compulsive gambling (D. Minn.), 341

MIRCERA

Anemia drug, sales ban upheld (Fed. Cir.), 1097

MIRENA

Heavy menstrual bleeding treatment approved by FDA, 1177

MISSOURI

Medicaid fraud, state settles with pharmacy, 975

MUCINEX D

Pseudoephedrine HCl, generic ANDA challenged by patent holder, 690

MULTAQ

Irregular heartbeat drug, FDA panel favors approval, 350; approved, 810

MYFORTIC

Organ rejection drug maker warns of anemia risk, 1051

N**NALFON**

Pain drug, FDA warns direct mailer on false or misleading advertising, 1050

NAMENDA

Alzheimer's drug generic challenge, some firms dismissed (D. Del.), 1100

NANOTECHNOLOGY

Collaboration announced by FDA, 291

NAPRELAN

Anti-inflammatory drug infringement suit dismissed (S.D. Fla.), 284

NAROPIN

Anesthetic, generic blocked (D.N.J.), 907; appealed, 1035

NATIONAL INSTITUTES OF HEALTH (NIH)

Director confirmed, 948

NATRECOR

Heart drug off-label use, feds intervene (N.D. Cal.), 226

NEO-SYNEPHRINE

Nasal decongestant addiction, suit time-barred (N.D. Ill.), 177

NEUROTONIN

Bulger suicide suit dropped on first day of testimony (D. Mass.), 914
Epilepsy drug, causation evidence permitted in suicide suit over off-label use (D. Mass.), 556; class certification denied, 612
Epilepsy drug, monopoly claim against maker may proceed (D.N.J.), 1026
Monopoly claim against maker may proceed (D.N.J.), 1026
Off-label uses, decertification challenged (Pa. Super. Ct.), 770
Patient class decertified in off-label use suit (Pa. Ct. Com. Pl.), 258
Widow of suicide victim sues, off-label use alleged (D. Minn.), 588

NEW HAMPSHIRE

Adverse events reporting bill signed, 921
Data mining, ban on prescription data sales upheld (U.S., rev sought), 363; other states await ruling, 544; (rev den), 763
Privacy, shredding of health records, requirement considered, 184

NEW JERSEY

Internet pharmacies regulation, Assembly approves, 321

NEW MEXICO

Privacy, state considers requiring notification of E-health breaches, 184

NEW YORK

Budget includes lower drug costs and bans industry gifts to MDs, 20; signed, 444
Discounts, low-income drug card plan launched, 348
Generic use down upstate, 209
Pharmacies
—Chains agree to free language services, 474
—Language assistance required in N.Y.C., 1080

NEXIUM

Heartburn drug, false advertising class action remanded (3rd Cir.), 587

NICODERM

Canadian pricing hearing, challenge rejected, 1239

NIFEDIPINE

Generic hypertension drug, direct purchasers antitrust class action certified (D.C. Cir.), 229

NIGERIA

Trovan clinical trial claims
—Kano settles with Pfizer, 913
Trovan settlement, hearing planned on claim that Pfizer tried to circumvent victims' attorneys (Conn. Super. Ct.), 616

NORTH CAROLINA

Medicaid fraud recoveries reported for 2008, 47
Unused drugs and devices, donation bill signed, 950

NORVASC

Blood pressure and angina drug patent invalidated by Canadian court, 839; reasons released, 1057

NORVIR

Antitrust, maker cleared of monopoly charges (9th Cir.), 791; rehearing denied, 987; Analysis & Perspective, 1011
Pricing
—AIDS drug price settlement approved (N.D. Cal.), 942

NUVARING

Contraceptive product liability, defendants barred from conducting ex parte interviews with treating MDs (E.D. Mo.), 367

O**OFF-LABEL USE**

Actimmune. *See* ACTIMMUNE
Aranesp class action dismissed (C.D. Cal.), 730
Bextra marketing, ex-sales manager pleads guilty (D. Mass.), 370; sentenced, 736
Botox maker seeks to block FDA enforcement (D.D.C.), 1163
Cancer drug studies vary in quality, 1258
Cephalon class action dismissed (D.N.J.), 1196
Destruction of documents, ex-manager convicted of obstruction of justice (D. Mass.), 316; sentenced, 885
Enforcement, increased scrutiny predicted, Special Report, 420
False claims. *See* FALSE CLAIMS
Forest Labs settles false claims (D. Mass.), 1166
Guidance on promotion offered by legal experts, 745
Lovenox qui tam suit may proceed (N.D. Ill.), 501
Medicare
—Coverage conditions more complex for drugs than devices, 382
—State Attys. Gen. support CMS proposal to block insurers' requirement, 345
Neurotonin. *See* NEUROTONIN
Pediatric products, Special Report, 572
Regulatory outlook 2009, 80

OFF-LABEL USE —Contd.

“Reprint practices,” FDA issues guidance, 65
RICO. *See* RACKETEER INFLUENCED AND
 CORRUPT ORGANIZATIONS (RICO) ACT
 RU-486, prescribing for off-label use banned (Ohio),
 794; remanded (6th Cir.), 943
 Schering illegal marketing allegations dismissed
 (D.N.J.), 855
 Zyprexa marketing. *See* ZYPREXA

OHIO

RU-486, prescribing for off-label use banned (Ohio),
 794; remanded (6th Cir.), 943

OMNICEF

Antibiotic, generic created by different process now
 infringement (Fed. Cir.), 605

ONGLYZA

Diabetes drug approved by FDA, 922
 Diabetes drug, FDA panel favors approval, 414;
 application, timeline extended, 513

ONSOLSIS

Cancer drug approved, 867

OPANA ER

Painkiller, patent infringement suit over generic
 dismissed (D.N.J.), 230

OREGON

Adverse event reporting system, few pharmacies
 participating, 950

ORGAN TRANSPLANTS

Anti-rejection drug copy, FDA may approve (D.D.C.),
 967
 Generic immunosuppressants, FDA denies petition to
 additional measures to protect transplant recipients,
 951
 TOL101, In Brief, 451

ORLISTAT

Obesity drug and liver injury, FDA reviews adverse
 events, 1002

ORPHAN DRUGS

DNage BV, In Brief, 515
 Grant program planned by FDA for clinical trials, 18
 HPN-100, In Brief, 18; designation received, 541
 KRX-0401, In Brief, 1084
 Oxyocyte, In Brief, 571
 Paclical, In Brief, 451
 Qutenza, In Brief, 656
 Restanza, In Brief, 1084
 RiaSTAP approved for bleeding in patients with
 congenital fibrinogen deficiency, 102; approved, In
 Brief, 299
 TOL101, In Brief, 451

ORTHO TRI-CYCLEN

Contraceptive maker challenges generic (D.N.J.), 733;
 generic maker halts shipments, 836; settled, 879

OVCON

Chewable contraceptive formulation, antitrust
 settlement reached (D.D.C.), 12

OXYCONTIN

Misbranding, Purdue Frederick ex-execs barred from
 federal programs, 119

P**PATADAY**

Allergy eye drug ANDA, infringement claimed (S.D.
 Ind.), 63
 Eyedrop ANDA, infringement alleged (S.D. Ind.), 202

PATANOL

Eye treatment generic, infringement alleged (S.D.
 Ind.), 202

PATENTS

Acular patent upheld (U.S., rev den), 117
 ADX-N05, In Brief, 570
 Alzheimer's treatment patent invalid (Fed. Cir.), 1128
 Amrix infringement claim split from antitrust and
 patent misuse claims (D. Del.), 1192
 Antara, Lupin gets marketing rights (D. Md.), 1194
 Anti-interleukin antibiotics, infringement alleged (D.
 Mass.), 939
 Antidepressant competing patents, two claims
 invalidated by prior art (S.D.N.Y.), 673
 Appointments, PTO chief confirmed, 949
 Azopt maker alleges infringement (E.D. Tex.), 119
 BiTE antibody, In Brief, 77
 BNA plans audiocconference, In Brief, 190
 Brazil, pipeline law challenged, 597
 Cabilly II, PTO confirms claims of validity, 270
 Calibrating proper dosage for treating certain diseases,
 method is patentable (Fed. Cir.), 1066; Analysis &
 Perspective, 1209
 Carvedilol, infringement claim settled (D.N.J.), 587
 Celixa competing patents, two claims invalidated by
 prior art (S.D.N.Y.), 673; jury awards royalty, 1247
 Cephem compound double patent challenge, summary
 judgment vacated (Fed. Cir.), 433
 Cipro. *See* CIPRO
 Clarinex patent suit settled (D.N.J.), 437
 Clobel patent infringement alleged (N.D. Tex.), 63
 Detrol maker did not mislead PTO in prosecuting
 patent (D.N.J.), 461
 Enbrel, non-infringement ruling affirmed (Fed. Cir.),
 635
 Enforcement focused on drug patent settlements,
 Analysis & Perspective, 1006
 Exclusivity, FDA delisting rule challenged (D.D.C.),
 792; upheld, 964; Analysis & Perspective, 979
 Expiration of patent does not increase use, report finds,
 1264
 Focalin, infringement claim dismissed (D.N.J.), 95
 Fosrenol maker alleges infringement (S.D.N.Y.), 312
 Generic drugs. *See* GENERIC DRUGS
 High priority changes urged at PTO, In Brief, 19
 Humira. *See* HUMIRA
 “Imminent importation” of allegedly infringing drugs,
 revised opinion issued (Fed. Cir.), 524
 Infringement
 —AIDS therapy, Stanford lacks standing to make
 infringement claim (Fed. Cir.), 1167
 Levaquin. *See* LEVAQUIN
 Lexapro. *See* LEXAPRO
 Licensing
 —Antibody license, In Brief, 192
 —Aricept licensing, In Brief, 299
 —Assay licensing, In Brief, 77
 —AV513 license, In Brief, 25
 —Axomadol licensing, In Brief, 272
 —Blinatumomab licensing, In Brief, 324
 —Budesonide license, In Brief, 838
 —Caerulomycin A license, In Brief, 238
 —Campath, Genzyme buys rights, 384
 —CDA-1 and CDB-2 license, In Brief, 486
 —Cimzia licensing, In Brief, 191
 —Daxas, In Brief, 952
 —Depression drugs licensing, In Brief, 191
 —DI-Leu16-IL2 license, In Brief, 323
 —DOTPA chloride license, In Brief, 238
 —Elinogrel rights, In Brief, 213
 —Fanapt, In Brief, 1208
 —Fortesta, In Brief, 1004
 —Heart drug licenses, In Brief, 627
 —IDX889 licensing, In Brief, 191
 —JAK2 inhibitors licensed to Onyx, 48
 —JP-1730/fipamezole U.S.-Canadian rights
 purchased, 1003
 —Lupuzar license, In Brief, 163
 —OpRA III licensing, In Brief, 1116
 —Pain drug licensing, In Brief, 191
 —POT-4, In Brief, 1265
 —Relistor, In Brief, 1238
 —Reloxin license, In Brief, 450
 —RNA-based compounds, In Brief, 1207
 —Tetrabenazine licensing, In Brief, 595
 —UCB drug rights, In Brief, 77
 —VIA licenses, In Brief, 24
 —Wellbutrin, U.S. rights purchased, In Brief, 540
 —Zevalin licensing, In Brief, 78
 Lipitor. *See* LIPITOR
 Lotrel. *See* LOTREL
 Lovenox patent not enforceable (U.S., rev sought),
 171; (rev den), 495
 “Machine or transformation” test questioned (U.S.,
 briefs filed), 939
 Messenger protein, patent invalid for lack of adequate
 written description (Fed. Cir.), 399
 Milestone payments, In Brief, 77
 Naprelan infringement suit dismissed (S.D. Fla.), 284
 Oforta, In Brief, 570
 Pataday. *See* PATADAY
 Plavix active ingredient, patent not invalid for
 anticipation or obviousness (U.S., rev sought), 912
 Prosecution process, PTO may issue rules changing
 (Fed. Cir.), 337; rehearing sought, 669; rehearing
 granted, 789; stay of en banc review sought, 879;
 PTO to rescind rules, 1201; challenge proceeds,
 1224
 Reform
 —Conditions for patentability. *See* LEGISLATION,
 FEDERAL, S 610
 —Congress urged to scale back controversial
 proposals, 186
 —CRS publishes analysis, 128
 —First-to-file. *See* LEGISLATION, FEDERAL, HR
 1260, S 515
 —Urged at PTO, 43
 Reversing patent settlements, Analysis & Perspective,
 749
 Risk evaluation and mitigation strategy patents,
 Analysis & Perspective, 28
 Rhythmol SR patent dispute settled (D. Del.), 463
 Skelaxin method patents invalid (E.D.N.Y.), 92
 Solodyn. *See* SOLODYN
 Tarcera infringement suit dismissed in India, 543
 Truvada V drug ANDA infringes patent (S.D.N.Y.),
 10
 Ultracet patent invalidity ruling partially reversed
 (Fed. Cir.), 1025
 Ultram ER patent invalid for obviousness (D. Del.),
 963; appealed, 1034
 Unenforceable patents, direct buyer plaintiffs have
 standing to bring antitrust claim (2nd Cir.), 1217
 Unpatentable law of nature, gene expression at issue
 (Fed. Cir.), 172; rehearing granted, 988
 Yasmin patent invalid for obviousness (Fed. Cir.), 937

PAXIL

Antidepressant product liability settlement approved
 (D.P.R.), 282
 Birth defects
 —Production of study correspondence ordered (D.
 Mass.), 1101
 Failure-to-warn of suicide risk, no preemption (E.D.
 Wis.), 910
 Generic, supply and license contract dispute, \$70M
 awarded for breach (N.D. Ill.), 201
 Venue change sought in product liability suit (E.D.
 Pa.), 1032; severance sought, 1066
 Wrongful death action by stepchildren barred (Tex.
 App.), 800

PBM *See* PHARMACY BENEFITS
 MANAGEMENT (PBM)**PEGINTRON**

Melanoma drug cleared by FDA panel, 1176

PENNSYLVANIA

Price database launched, 293

PERAMIVIR

H1n1 virus treatment, FDA clears for emergency use, 1261

PERSONALIZED MEDICINE

Comparative effectiveness discussed at conference, 1265

Key trend in biotech industry, 568

Merck CEO urges, 566

R&D advocates push, 538

PHARMACISTS AND PHARMACIES

CVS accused of failing to protect patient data (FTC), 199; pharmacists seek probe, 351

Electronic prescriptions. *See* E-PRESCRIPTIONS

Health care reform, Senate bill includes PBM transparency, 1128

Medicare accreditation. *See* LEGISLATION, FEDERAL, HR 3663

N.Y. chains agree to free language services, 474

Ore. adverse event reporting system, few pharmacies participating, 950

"Pill mill," pharmacist convicted (Kan. Dist. Ct.), In Brief, 617

Plan B, pharmacists challenge to Ill. contraceptive dispensing requirement may proceed (Ill.), 7

Rhabdomyolysis blamed on drug interaction, pharmacy had no duty to warn (N.D. Ind.), 857

Tenn., disclosing drug cost information, bill passed, 621

Wal-Mart settles recordkeeping charges, 46

Walgreens accused of fraudulently switching dosage forms, dismissed (N.D. Ill.), 1030

PHARMACISTS AND PHARMACISTS

New york

—Language assistance required in N.Y.C., 1080

PHARMACY BENEFITS MANAGEMENT (PBM)

Antitrust, Internet pharmacy denied access to PBM networks, claim time-barred (5th Cir.), 527

D.C. PBM disclosure law preempted (D.D.C.), 333

Express Scripts to buy WellPoint PBMs, 448

Transparency. *See* LEGISLATION, FEDERAL, HR 3200

PHENERGAN

Anti-nausea drug "IV push" blamed for gangrene and loss of guitar player's arm, failure to warn claim not preempted (U.S.), 249; Analysis & Perspective, 353; preemption limits, Analysis & Perspective, 388; discussed at conference, 564; effect on preemption defense, Analysis & Perspective, 658

PHYSICIANS

Conflicts of interest

—AstraZeneca to disclose payment to health care professionals who speak on its behalf, 623

—Codes of conduct urged by industry group, 236

—Gifts. *See* Gifts, *this heading*

—Harvard Medical School to revise policy, 161

—Increased disclosure sought by IOM, 511

—Industry ties to MDs, MedPAC reports, 266

—Medical students

—Industry funding under Senate scrutiny, 887

—Promotional items may influence unconscious attitudes, 569

—Naval Medical Center MDs, Grassley (R-Iowa) probes industry payments, 890

—Pfizer to disclose payments to health care professionals for consulting, speaking engagements, clinical trials, 189

—Professional medical associations urged to reject industry funding, 380

—Stanford med school to post MD-industry ties, 416

Gifts

—Conn. ban urged, 293

—Federal reporting bill. *See* LEGISLATION, FEDERAL, S 301

—Iowa Senate approves ban, 349

—Mass. limits criticized, 71; conferences moved from Boston, 129; creates controversy, 158; final rules adopted, 292

—Minn. bill to ban withdrawn, 378

—N.Y. budget proposal includes industry gift ban, 20

—Sunshine act, passages in 2009 predicted, 289

Pondimin, prescribing MD is not seller entitled to indemnity from maker (Tex. App. Ct.), 641

PLAN B *See* CONTRACEPTION

PLAVIX

Active ingredient, patent not invalid for anticipation or obviousness (U.S., rev sought), 912

Antiplatelet drug, less effective in some patients, FDA reports, 133

Antitrust, former executive pleads guilty to false statements (D.D.C.), 401

Independence Blue Cross placement of Plavix in highest tier upheld (E.D. Pa.), 707

Infringement settlement (D.N.J.), In Brief, 972

POLYHEME

Red blood cell substitute, maker shuts down, 594

PONDIMIN

Diet drug, prescribing MD is not seller entitled to indemnity from maker (Tex. App. Ct.), 641

PRANDIN

Diabetes drug patent validity, summary judgment denied (E.D. Mich.), 733

PRASUGREL

Antiplatelet drug, FDA panel favors approval, 159; consumer group opposes, 649

PREMPRO

HRT blamed for breast cancer, damage amount sealed (Pa. Ct. Com. Pl.), 1252

PRICING

Ala. pharmacies suit over reimbursement, summary judgment denied (M.D. Ala.), 312

Antitrust, Community Medical suit against drug maker over price may proceed (D. Minn.), 1218

Brand name prices up in 2008, 481

Canada. *See* CANADA

EU, cheaper drugs, drug makers suspected of blocking, 813

International developments

—Brazil authorizes price hikes, 387

—Mexico, Kaletra price cut, 387

—Switzerland, erectile dysfunction drugs price-fixing alleged, 214

Isentress price cut sought, 892

Lamictal sold at discount, no settlement breach (D.N.J.), 763

Lundbeck pricing suit may proceed (D. Minn.), 851

McKesson settles price inflation claims (D. Mass.), 909

Medicaid. *See* MEDICAID

Medicare

—Part B, changes to save money urged by HHS IG, 17

—Price comparison tool at CMS criticized, 864

Minn. generic pricing law, union funds sue pharmacy chains (D. Minn.), 1029

Norvir. *See* NORVIR

RICO suit brought by third-party payer over prices, settlement approved (D. Mass.), 307; appeal planned, 500; challenged, 553; upheld (1st Cir.), 1022

State developments

—Cal. counties denied class certification in suit against drug firms (N.D. Cal.), 611

—Pa. price database launched, 293

—Wis. Atty. Gen. settles with drug firms (Wis. Cir. Ct.), 11

PRIOLOSEC

Food poisoning, maker accused of failure to warn (S.D. Ohio), 680

Impax generic infringing valid patent (U.S., rev sought), 147; (rev den), 282

Ulcer drug, generic did not infringe (S.D.N.Y.), 309

PRIVACY AND CONFIDENTIALITY

CVS accused of failing to protect patient data (FTC), 199; pharmacists seek probe, 351

Data mining. *See* DATA MINING

De-identified health information and state regulation, Analysis & Perspective, 422

State developments

—N.H. considers requiring shredding of health records, 184

—N.M. considers requiring notification of E-health breaches, 184

—Trends, more states consider limits on health data marketing, 184

—Va. considers requiring notification of health data breaches, 184

PROCRIT

Anemia drug, qui tam suit against maker partially dismissed (1st Cir.), 968

PRODUCT LIABILITY

Accutane blamed for inflammatory bowel disease, new trial ordered (N.J. Super. Ct.), 313

Accutane, jury verdict for plaintiff thrown out (Fla. Dist. Ct. App.), 1252

Aldara blamed for severe skin symptoms, claim time-barred (D. Utah), 257

Aredia blamed for osteoporosis, summary judgment denied (M.D. Tenn.), 995

Avandia. *See* AVANDIA

Blood factor concentrates, Taiwanese hemophiliacs suits may proceed in Cal. (N.D. Ill.), 96

Chantix. *See* CHANTIX

Cholesterol drug unfavorable trial results, class action settled (D.N.J.), 908

Digitek. *See* DIGITEK

Effexor blamed for suicide, jury verdict for drug maker upheld (7th Cir.), 230

Elidel suits remanded (D.N.J.), 734

Etodolac contamination blamed for death, summary judgment granted for maker (E.D. Pa.), 708

Expert witnesses. *See* EXPERT WITNESSES

Federal preemption in drug and device suits, Analysis & Perspective, 106

Fosamax. *See* FOSAMAX

Heparin adverse reaction, suit remanded to state court (S.D. Ala.), 255

HRT. *See* HORMONE REPLACEMENT

THERAPY (HRT)

Injection devices, injuries blamed on continuous use (C.D. Cal.), 528

Ketek, concealment of hazards alleged, depositions blocked (E.D.N.Y.), 557

Legal outlook 2009, 79

Methamphetamine costs incurred by government entities, ephedrine and pseudoephedrine makers not liable (8th Cir.), 39

Metoclopramide. *See* METOCLOPRAMIDE

Minocin, failure-to-warn claim not preempted (N.D. Ill.), 364

Neo-Synephrine addiction, suit time-barred (N.D. Ill.), 177

Neurotonin. *See* NEUROTONIN

Nuvaring, defendants barred from conducting ex parte interviews with treating MDs (E.D. Mo.), 367

Obama preemption memo reviewed, 841

Outlook 2009, 135

Pain patch

—Design defect claim, strict liability does not apply (D. Utah), 912

PRODUCT LIABILITY —Contd.

Pain patch —Contd.

—Fatal dose, suit may proceed (S.D. W.Va.), 1228

Pain pump

—Access to settlement agreement ordered (S.D. Ind.), 1104

—Cause of action not stated, drugmakers dismissed as defendants (D. Colo.), 1196

—Expert witnesses. *See* EXPERT WITNESSESPaxil. *See* PAXIL

Phenergan blamed for gangrene and loss of guitar player's arm, failure to warn claim not preempted (U.S.), 249; Analysis & Perspective, 353; preemption limits, Analysis & Perspective, 388; discussed at conference, 564; effect on preemption defense, Analysis & Perspective, 658

Pondimin, prescribing MD is not seller entitled to indemnity from maker (Tex. App. Ct.), 641

Prilosec, maker accused of failure to warn of food poisoning risk (S.D. Ohio), 680

Redux, FDA approval preempts failure-to-warn claim (N.D. Ohio), 366

Reglan. *See* REGLAN

Remicide, blamed for pulmonary fibrosis, key expert excluded (11th Cir.), 203

Seroquel. *See* SEROQUEL

State developments

—Ga. governor proposes protection for drug and device makers, 209

—Mich. House approves repeal of immunity for drug firms, 378

Sulindac blamed for SJS, federal law no bar to suit (D.N.H.), 1190

Trasylol suit remanded to state court (S.D. Ill.), 1227
Trileptal blamed for multi-organ sensitivity, suit dismissed (S.D. Ohio), 970

Ulcer drug recall, plaintiff had no side effects denied, claim dismissed (N.D. Cal.), 529

Vioxx. *See* VIOXX

Vytorin misrepresentation claims, makers submit FDA evaluation on effectiveness (D.N.J.), 176

Yasmin blamed for blood clots, consolidation of suits sought (J.P.M.L.), 882

Zometa. *See* ZOMETAZyprexa. *See* ZYPREXA**PROLIA**

Osteoporosis treatment, approval recommended by FDA panel, 808

PROPOXYPHENE

Pain drug risks, FDA panel recommends taking off market, 155

Pain drugs, FDA orders boxed warning, 803

PROPYLTHIOUACIL

Hyperthyroidism drug, liver risk cited, 646

PROTONIX

Acid suppressant drugs, Medicaid overcharges alleged (D. Mass.), 582

Generic

—Erosive esophagitis treatment, motion to enjoin generic denied (Fed. Cir.), 585

—Gastroesophageal reflux drug, generic advertising challenged (E.D. Mich.), 554

PROVENGE

Prostate cancer drug application planned, 1147

Prostate drug, politically-motivated delay in approval alleged, dismissal affirmed (U.S., rev den), 61

PROVIGIL

Narcolepsy drug off-label marketing, dismissal denied (E.D. Pa.), 996

PULMICORT

Asthma drug maker seeks to block generic (D.N.J.), 436; blocked, 461; preliminary injunction, 610

PURCHASING POOLS

Savings for group purchasing organizations reported, 539

R**RACKETEER INFLUENCED AND CORRUPT ORGANIZATIONS (RICO) ACT**

Epogen and Aranesp off-label promotion, RICO does not apply (C.D. Cal.), 37

Provigil and Gabitril off-label marketing, dismissal denied (E.D. Pa.), 996

Third-party payer suit over prices, settlement approved (D. Mass.), 307; appeal planned, 500; challenged, 553; upheld (1st Cir.), 1022

Trasylol, RICO suit against surgery drug maker dismissed (S.D. Fla.), 965

RAPTIVA

Psoriasis drug adverse events, FDA issues advisory, 233

Pulled from market, link to fatal nervous system disorder cited, 413

REDUX

Diet drug, FDA approval preempts failure to warn claim (N.D. Ohio), 366

REGLAN

Gastrointestinal reflux drug blamed for movement disorder, failure-to-warn claim against generic maker not preempted (D. Vt.), 6; review denied, 465

Jurisdiction, liability suit properly removed to federal court (E.D. Pa.), 529

Neurological movement disorder blamed on drug, failure-to-warn claim not preempted (W.D. Okla.), 310

Tardive dyskinesia blamed on generic drug, brand-name maker not liable (W.D. Ark.), 614

RELENZA

Death risk from inhalation powder, FDA issues warning, 1206

REMICADE

Arthritis drug product liability, medical malpractice defendants severed (N.D. Ohio), 798

Distribution agreement, arbitration sought, 622

Pulmonary fibrosis blamed on drug, key expert excluded (11th Cir.), 203

REPLAGAL

Fabry disease treatment, maker plans license application, 1236

REPORTING REQUIREMENTS

Clinical trials

—Investigator may be criminally liable for not following FDA reporting requirements (5th Cir.), 175

—Registries use up, reporting requirements of journals and agencies cited, 410

Electronic filing of drug data, FDA issues guidance, 645

Physician gifts. *See* LEGISLATION, FEDERAL, 301**RESEARCH AND DEVELOPMENT (R&D) *See****also* CLINICAL TRIALSAntibiotics. *See* ANTIBIOTICS

Antibodies

—HGS and Morphotek, In Brief, 386

—Synagava and Morphotek, In Brief, 812

ARX424, In Brief, 237

Betrixaban, In Brief, 838

Bifeprunox, In Brief, 927

Biologics. *See* BIOLOGICSCancer. *See* CANCER

Ceftaroline in development, 977

Cetorelix pamoate, In Brief, 298

Combination drugs. *See* COMBINATION DRUGS
Contract research groups, BNA plan audioconference, 297

Cordex and Cato BioVentures, In Brief, 238

Debio 0928, In Brief, 748

Diabetes drugs in development, 594; Debiopharm

Group and Mercury Therapeutics, In Brief, 926

DXL625, In Brief, 271

Elesclomol, In Brief, 720

Eli Lilly, In Brief, 1085

Endo and Alexa, In Brief, 164

EU signs off on public-private partnership projects, 628

ExonHit collaborating with Allergan, 47

Factor VIIa, In Brief, 782

FASgen and Centocor, In Brief, 50

Funding reported for 2008, 297

Genyous, In Brief, 164

Huntington's drugs, In Brief, 515

IC14, In Brief, 570

ImQuest and Arisyn, In Brief, 515

Influenza drug development, FDA drafts guidance, 233

J&J and Crucell collaboration, In Brief, 1149

Malaria, In Brief, 485

Merck and Cardione, In Brief, 451

MS treatment, In Brief, 77; 77

Nanotechnology collaboration announced by FDA, 291

Neurological disease drugs, In Brief, 450

Ophthalmic conditions, In Brief, 516

Personalized medicine pushed by R&D advocates, 538

Pimavanserin tartrate, 541

Riquent, In Brief, 50

STP-206, 418

Therapeutic peptides research increasing, 654

Tuberculosis, In Brief, 720

UDB, In Brief, 25

Udenafil, In Brief, 50

Unpromising drug candidates, firms accused of aggressively ending work, 870

Urocidin, In Brief, 838

Wyeth to collaborate with Pharma, In Brief, 77

RESTANZA

Pneumonia, drug called safe, but not effective by FDA panel, 649

RIASTAP

Orphan drug approved for bleeding in patients with congenital fibrinogen deficiency, 102; approval, In Brief, 299

RICO *See* RACKETEER INFLUENCED AND CORRUPT ORGANIZATIONS (RICO) ACT**RIMONABANT**

Obesity drug securities fraud suit dismissed (S.D.N.Y.), 1135

RISPERDAL

Application, In Brief, 213

Bipolar disorder, In Brief, 595

Generic

—Approved, In Brief, 164

—Jurisdiction lacking to hear patent counterclaims (U.S., rev den), 340

—Marketed, In Brief, 656

Schizophrenia drug, Tex Atty. Gen. amends Medicaid false claims complaint (Tex. Dist. Ct.), 14

RITUXAN

Arthritis drug associated with brain disease, 1261

RIVAROXABAN

Anti-clotting drug gets favorable review from FDA panel, 351; gets complete response letter, 650

ROCEPHIN

Infection treatment, FDA revises prescription information, 447

ROMIDEPSIN

Lymphoma drug, approval urged by FDA panel, 1050

RYTHMOL SR

Heart drug patent dispute settled (D. Del.), 463

S

SABRIL

Adult seizure drug approved, 1003
Epilepsy drug cleared by FDA panel, 73

SAFETY *See also* ADVERSE EFFECTS; ADVERSE EVENTS; WARNINGS

Acetaminophen in prescription drugs, FDA panel urges ban, 802
Actavis manufacturing, FDA seeks to bar drugmaking at N.J. facility (D.N.J.), 61
ADHD drugs tied to cardiac deaths, FDA reports, 714
Asthma drugs and suicidal behavior, FDA continues review, 74
Biologics plant shutdown, 718; to reopen, 869
Botox, FDA announces new safety measures, 534; gets boxed warning, 919
Cambrex Italy facility, FDA finds violations, 1003
Canadian firms, FDA warns on manufacturing practices, 837
Caraco drugs seized by FDA, 781
CellCept. *See* CELLCEPT
Cold products may affect sense of smell, FDA says, 718
Collaboration urged by FDA official, 1079
Combination drugs, safety rule proposed by FDA, 1173
Consumer risk-benefit information, simplification sought, 267
Counties seek reclamation of drugs by firms, 925
Digoxin recall, In Brief, 385
Disposal of drugs, In Brief, 1203
Duragesic pain patch lots recalled, 46
Electronic safety reporting mandate proposed by FDA, 998
Ethex recall expanded, In Brief, 163
Exjade associated with renal failure, 1145
Flucloxacillin associated with liver damage, 652
Foreign drugs
—Globalization raises issues for FDA, 506
—India, FDA opens offices, 99
—Parity in inspections. *See* LEGISLATION, FEDERAL, HR 759
—Pilot safety program launched by FDA, 99
Heparin. *See* HEPARIN
Insulin pen sharing, In Brief, 377
KV stops tablet shipments, 22; suspends manufacturing and shipping of all products, 132; agrees to manufacturing injunction (E.D. Mo.), 251
Lantus, FDA examines cancer risk, 809
Liraglutide cancer risk disputed, 414
Liver injury, FDA issues guidance, 888
Macroboid recall, In Brief, 541
Maxipime, no higher mortality risk reported by FDA, 716
Medicated patches and MRIs, FDA issues warning, 289
Melamine testing, FDA issues guidance, 949
Methadone use, In Brief, 510
Mitigating risk, FDA offers draft guidance for industry, 1141
Mixed salts recalled, 976
Mylan W.Va. facility cleared by FDA, 976
New molecular entities, FDA completes post-marketing safety pilot project, 1232
Opioids, FDA will require risk evaluation and mitigation strategies, 182; pushed by stakeholders, 644
Opioids, FDA warns firms marketing unapproved drugs, 1206
Oversight
—Communicating risk, panel offers advice for FDA, 532

—Foreign drugs. *See* Foreign drugs, *this heading*
—Increased FDA inspection resources. *See* LEGISLATION, FEDERAL, S 882
—Legal outlook 2009, 79
—More resources urged for FDA, 102
—Proprietary drug names, FDA issues review information software, 206
—Regulatory outlook 2009, 80
—Risk advisory panel, FDA seeks candidates, 1044
—Sentinel Initiative at FDA, Senators want updates, 69
Propafenone HCl recall, In Brief, 352
Propofol recall, In Brief, 871
Propoxyphene, FDA panel recommends taking off market, 155
Proprietary drug name review, FDA plans pilot program, 1141
Propylthiouracil, liver risk cited, 646
Ranbaxy plant, FDA says data falsified, 235
Raptiva. *See* RAPTIVA
Relenza, FDA issues warning, 1206
Resources should be examined by FDA, GAO reports, 861
Rituxan associated with brain disease, 1261
Rocephin, FDA revises prescription information, 447
Sentinel Initiative, FDA plans to open docket, 533
Seroquel. *See* SEROQUEL
Shorter warning letter response times and more inspections predicted, 1000
Simponi and fungal infections, FDA warns providers, 651
Skin-numbing products, FDA issues advisory on side effects, 98
Strategic Plan for Risk Communication issued by FDA, 1142
Supply chain safety, FDA drafts guidance, 98
Toll-free number on medication guides, FDA issues guidance, 351
Transdermal patches recalled, 351
Trazodone, In Brief, 1208
Treanda patients, skin reaction reported, 513
Tysabri, In Brief, 486; 782
Tysabri, viral infections reported to FDA, 1113
Ultram ER lots recalled, 47
Unapproved drugs
—Narcotics, FDA warns firms to stop making and selling, 381; Lannett to continue marketing, 414; allowed for dying patients, 441
—Permanent injunction placed on Advent, 447
—Smuggling unapproved cancer drugs (C.D. Cal.), In Brief, 558
Vytorin, safety reviewed by FDA, 73
Wash., tamper-resistant prescription pad bill signed, 593
Weight loss supplement ingredients, FDA alerts consumers, 18
Xigris, FDA probes bleeding events and deaths, 160
Xolair, heart attack and stroke risk examined by FDA, 860
Zonegran may cause metabolic acidosis, FDA report, 236

SECURITIES

Adolor shareholder derivative suit dismissed (E.D. Pa.), 615
Alzheimer's drug, securities fraud class action dismissed (S.D.N.Y.), 369
Avandia, investors' security fraud suit dismissed (S.D.N.Y.), 992
Biotechs, fraud class actions "differed dramatically" in 2008, survey finds, 484
Blood clot drug misstatements, securities fraud class action dismissed (N.D. Cal.), 12
Blood thinner make accused of misrepresenting safety and prospects, dismissed (2nd Cir.), 770
Celebrex, investors suit over alleged clinical study misrepresentations timely (3rd Cir.), 150
Cosmetics firm accused of channel stuffing and failure to disclose acne drug problems (N.D. Cal.), 615

Derivative suit plaintiffs did not show futility of making pre-suit demand on Pfizer board (2nd Cir.), 120
Disclosure process and SEC filings, advice offered to firms, 479
Gilead accused of material misstatements about demand for Viread (U.S., rev den), 464
Hedge fund advisor settled SEC charges over disclosure and merger, 858
Merck
—Employees class action over alleged artificially inflated stock certified (D.N.J.), 361
—Stock drop claim may proceed (D.N.J.), 368
Omnicare suit dismissed (6th Cir.), 1254
Prostate drug, investors accuse maker of false statements (S.D.N.Y.), 259
Sanofi, rimonabant disclosure suit dismissed (S.D.N.Y.), 1135
Stiefel accused of undervaluing stock in buy-back scheme (S.D. Fla.), 828
Tysabri disclosures, In Brief, 1149
Vioxx maker accused of misrepresenting safety profile and commercial viability (U.S., rev grant), 608; suit improperly reinstated, 993
Viread maker accused of misrepresenting sales (N.D. Cal.), 679; some shareholder claims may proceed, 1229
Vytorin. *See* VYTORIN

SELZENTRY

HIV drug, FDA panel recommends approval, 1206

SERDOLECT

Schizophrenia drug, FDA panel favors approval for certain patient populations, 415

SEROQUEL

Adolescents, FDA panel backs use for mental illnesses, 715
Antipsychotic diabetes suits
—Causation, expert witness excluded (Del. Super. Ct.), 734
—Documents indicate maker suppressed negative trial results and downplayed diabetes risk (M.D. Fla.), 252; evidence of foreign actions excluded, 314
—Summary judgment granted for maker (M.D. Fla.), 152
False promotion suit remanded to state court (D.N.M.), 852
Generic
—Challenged (D.N.J.), 203
—Patent upheld (Fed. Cir.), 1127
Safety
—FDA panel says drug not safe for all patients, 446
—New indications raise safety concerns, 269
Unnecessary prescriptions, health benefit fund cannot recover from maker (M.D. Fla.), 880

SILENOR

Insomnia drug rejected by FDA, 446

SIMPONI

Approved for arthritis, 513
Fungal infections, FDA warns providers, 651

SINGULAIR

Anticompetitive tactics, class action voluntarily dismissed (D.N.J.), 1099
Asthma drug and suicidal behavior, FDA continues review, 74
Generic blocked (D.N.J.), 961

SKELAXIN

Muscle relaxant method patents invalid (E.D.N.Y.), 92

SOLODYN

Acne drug generic patent dispute settled (D. Del.), 337; consent agreement entered, 992
Proposed generic, infringement alleged (D. Del.), 705

SOTRADECOL

Varicose vein treatment, FDA says web pages are misleading, 1109

SOUTH CAROLINA

Zyprexa, Atty. Gen. settles fraudulent marketing suit (S.C. Cir. Ct.), 1249

STALEVO

Parkinson's drug infringement claims settled (D. Del.), 526

STATUTES OF LIMITATIONS

Neo-Synephrine addiction, suit time-barred (N.D. Ill.), 177

Taiwanese hemophiliacs claims against blood concentrate makers time-barred (N.D. Ill.), 466

STELARA

Psoriasis drug approved, 1146

STEM CELL RESEARCH

ALS trial, In Brief, 26
License agreement, In Brief, 541
Osiris and FDA, In Brief, 104

STRATTERA

ADHD drug direct infringement claim dismissed (D.N.J.), 609

SULINDAC

Anti-inflammatory drug blamed for SJS, federal law no bar to suit (D.N.H.), 1190

SUPREME COURT, U.S.

False Claims Act public disclosure jurisdiction limited (rev grant), 729

Generic drugs

—Lexapro, declaratory judgment against generic maker dismissed (rev den), 227

—Prilosec, generic infringed valid patent (U.S., rev sought), 147; (rev den), 282

—Risperdal, jurisdiction lacking to hear patent counterclaims (rev den), 340

N.H. ban on prescription data sales upheld (rev sought), 363; other states await ruling, 544; (rev den), 763

Patents

—Actos patent dispute, attorneys' fees upheld (rev den), 1166

—Acular patent upheld (rev den), 117

—Cipro settlement challenged (rev den), 730

—Generic drugs. *See* Generic drugs, *this heading*

—Lovenox patent not enforceable (rev sought), 171; (rev den), 495

—“Machine or transformation” test questioned (briefs filed), 939

Plavix

—Active ingredient, patent not invalid for anticipation or obviousness (rev sought), 912

Product liability

—Antidepressants, failure-to-warn of suicide risk, preemption ruling remanded (dec), 280

—Phenergan blamed for gangrene and loss of guitar player's arm, failure to warn claim not preempted (dec), 249; Analysis & Perspective, 353; preemption limits, Analysis & Perspective, 388; discussed at conference, 564; effect on preemption defense, Analysis & Perspective, 658

Provenge, politically-motivated delay in approval alleged, dismissal affirmed (rev den), 61

Securities, Gilead accused of material misstatements about demand for Viread (rev den), 464

Trovan clinical trials, maker accused of violating international norms (rev sought), 854

Vioxx maker accused of misrepresenting safety profile and commercial viability (rev grant), 608; suit improperly reinstated (dec), 993

SURFAXIN

Respiratory distress syndrome drug application, FDA wants more data, 477

SWINE FLU *See* H1N1 VIRUS**SWINE FLU OUTBREAK *See* INFLUENZA****SWITZERLAND**

Erectile dysfunction drugs, price-fixing alleged, 214

T**TARCERA**

Cancer drug patent infringement suit dismissed in India, 543

TAXATION

Swap-and-assign transactions were loans (D.N.J.), 1033

TENNESSEE

Disclosing drug cost information, bill passed, 621
TennCare dual eligibles reimbursed at 100 percent of Medicare charge, bill signed, 865

TEXAS**Medicaid**

—Immune system drug maker settles overcharge claims (Tex. Dist. Ct.), 969

Medicaid, false claims complaint against Risperdal makers amended (Tex. Dist. Ct.), 14

TOPAMAX

Anticonvulsant, generic exclusivity awarded by FDA, 469

Seizure drug, generic, In Brief, 385; approved, In Brief, 415

TRASYLOL

Bleeding drug product liability suit remanded to state court (S.D. Ill.), 1227

TREANDA

Lymphoma drug, skin reaction reported, 513

TRICOR

Anti-cholesterol drug, consumer suit over generic delay, settlement approved (D. Del.), 500

TRILEPTAL

Epilepsy drug blamed for multi-organ sensitivity, suit dismissed (S.D. Ohio), 970

TROVAN

Antibiotic clinical trials, maker accused of violating international norms (2nd Cir.), 147; (U.S., rev sought), 854

Nigerian clinical trial claims

—Kano settles with Pfizer, 913

Nigerian settlement, hearing planned on claim that Pfizer tried to circumvent victims' attorneys (Conn. Super. Ct.), 616

TRUVADA

HIV drug ANDA infringes patent (S.D.N.Y.), 10

TYSABRI

Disclosures, In Brief, 1149
MS drug maker breached collaboration pact (S.D.N.Y.), 1029

Viral infections reported to FDA, 1113

TYVASO

Hypertension drug approved, 923

U**ULTRACET**

Painkiller patent invalidity ruling partially reversed (Fed. Cir.), 1025

ULTRAM ER

Pain drug lots recalled, 47

Patent invalid for obviousness (D. Del.), 963; appealed, 1034

Web video called misleading by FDA, 623

UROXATRAL

Prostate drug, FDA calls promotional materials misleading, 1262

USER FEES

Increase announced by FDA, 918

V**VACCINES**

Cervarix. *See* CERVARIX

Cervarix cleared by FDA panel, 1234

Gardasil. *See* GARDASIL

Hiberix gets accelerated approval, 1002

J&J and Crucell collaboration, In Brief, 1149

PPD buys vaccine testing lab, 48

Recombivax HB, In Brief, 50

VALCYTE

Antiviral patent valid, generic does not infringe (D.N.J.), 1189; appealed, 1251

VANCOCIN

Antibiotic, FDA panel approves testing guidelines, 922

VANOS

Skin cream infringement dispute settled (W.D. Mich.), 463

VASOVIST INJECTION

Contrast imaging agent approved, 23

VELCADE

Cancer drug maker accused of overstating efficacy, 746

VERMONT

Data mining, ban on sale of prescription data by MDs upheld (D. Vt.), 495; firms denied injunction, 670

Gift ban for drug firms, expansion approved, 592; signed, 688

Marketing, spending by drug firms reported, 474

VIAGRA

Nonarteritic anterior ischemic optic neuropathy blamed on drug, causation expert barred (D. Minn.), 1040

VIOXX

Consumer class actions

—Cal., certification denied (Cal. Super. Ct.), 586

—N.J., certification denied (N.J. Super. Ct.), 340

Punitive damages vacated in failure-to-warn suit, appeal dismissed (N.J.), 1168

Securities fraud, maker accused of misrepresenting safety profile and commercial viability (U.S., rev grant), 608; suit improperly reinstated, 993

VIREAD

Antiretroviral drug maker accused of misrepresenting sales (N.D. Cal.), 679; some shareholder claims may proceed, 1229

Gilead accused of material misstatements about demand (U.S., rev den), 464

VIRGINIA

Privacy, state considers requiring notification of health data breaches, 184

VOTRIENT

Kidney cancer cleared by FDA panel, 1176; approved, 1235

VYTORIN

Cholesterol drug clinical trials, Waxman (D-Cal) and Stupak (D-Mich) seek more information, 233
 Misrepresentation claims, makers submit FDA evaluation on effectiveness (D.N.J.), 176
 Myopathy/rhabdomyolysis as side effect, dismissal sought (E.D. Tex.), 1102
 Negative trial data delayed, makers settle with states, 821
 Overcharging, makers to settle with purchasers (D.N.J.), 1247
 Safety reviewed by FDA, 73
 Securities
 —Concealment of adverse effects alleged (D.N.J.), 1035
 —Fiduciary breach over employee stock investments alleged (D.N.J.), 1032
 —Study results suit dismissed (D.N.J.), 1036
 Unfavorable trial results, class action settled (D.N.J.), 908

VYVANSE

ADHD drug exclusivity decision challenged (D.D.C.), 253; proceedings stayed, 434; FDA affirms exclusivity, 1256

W**WARFARIN**

Anticoagulant drug, Medicare to cover clinical trial, 946

WARNINGS *See also* LABELS AND PACKAGING; SAFETY

Fanapt approved for adult schizophrenia with warning, 539
 Myfortic maker warns of anemia risk, 1051
 Over-the-counter drugs, In Brief, 510
 Raptiva adverse events, FDA issues advisory, 233
 TNF blockers risk, FDA requires stronger warning, 918

WASHINGTON

Medicaid pharmacy reimbursement cuts blocked (W.D. Wash.), 403; agency to reexamine cuts, 592; agency to cut reimbursements, 621
 Plan B dispensing requirement, injunction vacated (9th Cir.), 823
 Tamper-resistant prescription pad bill signed, 593

WEIGHT LOSS PRODUCTS AND PROGRAMS

Combination drug blamed for death (E.D. Pa.), 438
 Expert disqualified in diet drug suit (E.D. Pa.), 825
 Fen-phen settlement, attorneys convicted of bilking plaintiffs (E.D. Ky.), 467
 Redux, FDA approval preempts failure-to-warn claim (N.D. Ohio), 366
 Repose law bars product liability claim (6th Cir.), 1039
 Rimonabant securities fraud suit dismissed (S.D.N.Y.), 1135

WELLBUTRIN

Antidepressant, direct purchaser antitrust suit may proceed (E.D. Pa.), 308
 Generic makers accused of making inferior product (Cal. Super. Ct.), 706
 U.S. rights purchased, In Brief, 540

WISCONSIN

Average wholesale price, Atty. Gen. settles with drug firms (Wis. Cir. Ct.), 11
 Medicaid, Pharmacia defrauded program through inflated prices (Wis. Cir. Ct.), 200; forfeitures sought, 556

WOMEN'S HEALTH

HRT. *See* HORMONE REPLACEMENT THERAPY (HRT)
 Mirena approved by FDA, 1177

WYOMING

Internet, drug database access bill signed, 321

X**XARELTO**

Anticoagulant makers plan to respond to FDA, 866

XELODA

Cancer drug, generic challenged (D.N.J.), 438

XIAFLEX

Arthritis drug, FDA panel urges approval, 1113

XIGRIS

Sepsis drug, FDA probes bleeding events and deaths, 160

XOLAIR

Asthma drug, heart attack and stroke risk examined by FDA, 860

XOPENEX

Asthma drug, dispute over generic settled (D. Del.), 286; generic launched, 1055

XYZAL

Antihistamine maker challenges generic (E.D.N.C.), 733
 Application for generic, In Brief, 747
 Approval, In Brief, 1005

Y**YASMIN**

Blood clots blamed on contraceptive, consolidation of suits sought (J.P.M.L.), 882
 Consolidation of product liability suits ordered (N.D. Ala., S.D. Ill.), 1169
 Patent invalid for obviousness (Fed. Cir.), 937

YAZ

Alleged misleading ads, false advertising claims dismissed (E.D. Cal.), 824; dismissal of amended complaint sought, 1102
 Blood clots blamed on drug, consolidation of suits sought (J.P.M.L.), 882
 Consolidation of product liability suits ordered (N.D. Ala., S.D. Ill.), 1169
 Contraceptive maker to submit TV ads to FDA, 189
 Severe complications blamed on drug, suits consolidated (Pa. Ct. Com. Pl.), 1104

Z**ZENPEP**

Exocrine pancreatic insufficiency drug approved by FDA, 1052

ZETIA

Cholesterol drug unfavorable trial results, class action settled (D.N.J.), 908
 Overcharging, makers to settle with purchasers (D.N.J.), 1247

ZITHROMAX

Approval, In Brief, 782

ZOMETA

Biophosphonates blamed for osteoporosis, summary judgment denied (M.D. Tenn.), 995
 Bone-building drug not withdrawn for safety or effectiveness reasons, FDA says, 448
 Economic and pain and suffering, plaintiff awarded damages (Mont. Dist. Ct.), 1254

ZONEGRAN

Epilepsy drug may cause metabolic acidosis, FDA report, 236

ZOSYN

Antibiotic, generic approval challenged (D.D.C.), 1099; TRO deneid, 1130

ZYPREXA

Adolescents, FDA panel backs use for mental illnesses, 715
 Antipsychotic drug overpayments, class certification for third party payers granted (2nd Cir.), 152
 Causation expert who stretched the truth disqualified (E.D.N.Y.), 587
 Diabetes and death blamed on drug, summary judgment denied (E.D.N.Y.), 1071
 Failure-to-warn suits time-barred (E.D.N.Y.), 768
 Illegal marketing, maker settles with Conn. Atty. Gen. (E.D.N.Y.), 1131
 Off-label uses, Lilly settles with Justice Dep't (E.D. Pa.), 93
 S.C. Atty. Gen. settles fraudulent marketing suit (S.C. Cir. Ct.), 1249
 Suicide blamed on drug, verdict for maker upheld (5th Cir.), 402
 Unresolved questions, summary judgment for maker denied (E.D.N.Y.), 995
 Warnings would not have changed usage, summary judgment for maker (E.D.N.Y.), 677